Stockwinners Market Radar for April 09, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:10 EDT Blizzard Entertainment, NetEase renew publishing agreement - The company states: "Video game titles from Blizzard Entertainment will return to the market sequentially, beginning this summer, under a renewed publishing deal Blizzard Entertainment, Microsoft (MSFT) Gaming, and NetEase (NTES) announced today. After continuing discussions over the past year, both Blizzard Entertainment and NetEase are thrilled to align on a path forward to once again support players in mainland China and are proud to reaffirm their commitment to delivering exceptional gaming experiences. The renewed publishing agreement will encompass games Chinese players had access to under the previous agreement: World of Warcraft(R), Hearthstone(R), and other titles in the Warcraft(R), Overwatch(R), Diablo(R), and StarCraft(R) universes. Building upon more than 15 years of past collaboration, Blizzard and NetEase are working diligently on relaunch plans, with further details to be shared at a later date."

20:01 EDT Itron selected by BREB in supporting construction more resilient grid - The company stated: "Itron announced that Bangladesh Rural Electrification Board, or BREB, a government organization and the largest power distributor in Bangladesh, has selected Itron to provide its Advanced Metering Infrastructure solution as the foundational technology to build a more resilient grid. This project supports a sustainable future in Bangladesh by helping to modernize BREB's distribution system. Included, BREB can empower its customers through greater visibility and control over their energy usage. Working together with Itron channel partner SQ Wire and Cable Co. Limited, BREB will install 500,000 smart pre-payment metering devices with Itron network interface cards, enabling automated meter reading, improved billing accuracy and reduced system losses. Additionally, its customers will benefit from time-of-use tariffs and detailed energy usage information accessed through a web portal, promoting smarter energy consumption, sustainability and cost savings."

19:50 EDT TRACON Pharmaceuticals trading halted, news pending

17:46 EDT Microsoft to invest $2.9B in AI, cloud infrastructure in Japan - Microsoft announced it will invest $2.9B over the next two years to increase its hyperscale cloud computing and AI infrastructure in Japan. It will also expand its digital skilling programs with the goal of providing AI skilling to more than 3M people over the next three years, open its first Microsoft Research Asia lab in Japan, and deepen its cybersecurity collaboration with the Government of Japan. "These investments aim to support Japan's key pillar to tackle deflation and stimulate the economy by expanding the infrastructure, skilled talent, and security required to accelerate Japan's digital transformation and adoption of AI," the company said. "The announcement coincides with Japanese Prime Minister Fumio Kishida's state visit to the United States, where he was joined by Microsoft Vice Chair and President Brad Smith, and Microsoft Japan President Miki Tsusaka." Reference Link

17:33 EDT ALX Oncology reports clinical data from Phase 1/2 trial of evorpacept - ALX Oncology Holdings reported encouraging clinical data from the ongoing Phase 1/2 investigator-sponsored trial, or IST, of evorpacept in combination with R2 in patients with indolent and aggressive R/R B-NHL. The new data were presented in an oral presentation at the 2024 American Association for Cancer Research Annual Meeting. The clinical trial enrolled a total of 20 patients with indolent and aggressive R/R B-NHL where all patients had received prior rituximab and 72% had received prior chemoimmunotherapy. Patients received evorpacept 30 mg/kg Q2W or 60 mg/kg Q4W in combination with standard R2 treatment. The regimen was well tolerated, and there were no dose-limiting toxicities. The maximum administered dose for evorpacept was 60 mg/kg Q4W. The most common adverse events due to any cause were fatigue, ALT increase, anemia, and AST increase, all of which were mostly low grade. There were no reported treatment-related deaths on study. Patients with indolent R/R B-NHL had a best ORR of 94% and a CRR of 83%. The median duration of response was not reached. The AUGMENT Phase 3 clinical trial1, a benchmark study in a similar patient population, reported an ORR of 78% and a CRR of 34% with R2 alone.

17:11 EDT Petco board terminates Chief Customer Officer Darren MacDonald - In a regulatory filing, the company stated: "On April 4, 2024, the Board of Directors of Petco Health and Wellness Company, Inc. approved the termination of employment of Darren MacDonald, the Company's Chief Customer Officer, effective as of April 12, 2024, which constitutes a termination of Mr. MacDonald's employment without cause under the Company's Executive Severance Plan. Subject to his execution of a release of claims, Mr. MacDonald will be eligible for the separation benefits set forth under the Company's Executive Severance Plan and his outstanding award agreements."

17:01 EDT Primis Financial announces notification of delinquency with Nasdaq - On April 4, 2024, Primis Financial Corp. received a letter from The NASDAQ Stock Market LLC indicating that, as a result of not having timely filed its Annual Report on Form 10-K for the year ended December 31, 2023 with the Securities and Exchange Commission, the company is not in compliance with NASDAQ Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the SEC. As previously disclosed in the Notification of Late Filing on Form 12b-25 filed on March 18, 2024 and Amendment No. 1 filed April 1, 2024, the Company expected to receive the Letter because it had not timely filed the 2023 Form 10-K with the SEC and the Company had determined that it required additional time in connection with the restatement of certain financial statements and ongoing "pre-clearance" process with the Office of the Chief Accountant of the Securities and Exchange Commission.

16:34 EDT IN8bio: Data for Gamma-Delta nsCAR-T cell therapy platform presented at AACR - IN8bio announced new preclinical data from its non-signaling gamma-delta T cell based Chimeric Antigen Receptor-T cell, nsCAR, platform, known as INB-300, that demonstrated improved selectivity to target leukemia cells while preserving healthy ones. The data support the potential for nsCAR to have a wider therapeutic window and to be used to prevent on-target off-tumor killing of healthy tissue that may express the CAR-T target. The data was presented in a poster session at the American Association for Cancer Research Annual Meeting 2024 on April 9 ...The new data presented at AACR included results from proprietary constructs targeting CD33 and/or CD123 for in vitro evaluation against various types of leukemia, including acute myeloid leukemia AML and chronic myeloid leukemia . The study results demonstrated notable differences between cells expressing traditional signaling CARs and those expressing the nsCAR constructs, which include a reduction in activation-induced cell death with nsCAR constructs.

16:31 EDT Victory Capital reports March AUM $170.3B vs. $164.9B in February - Victory Capital "reported Total Assets Under Management of $170.3B, Other Assets of $5.1B, and Total Client Assets of $175.5B, as of March 31, 2024. For the month of March, Average Total AUM was $167.6B, average Other Assets was $5.3B, and average Total Client Assets was $172.9B."

16:21 EDT Turtle Beach increases buyback authorization to $55M - Turtle Beach "announced its Board of Directors has modified its previously communicated near-term return of capital plan to shareholders, given the overwhelmingly positive reaction to the Company's recent transformational acquisition of Performance Designed Products and the strong underlying trading price of the Company's shares. With today's announcement, the Board of Directors no longer intends to launch the previously announced modified "Dutch auction" Tender Offer to purchase up to $30 million of its common stock at a price per share not less than $13.75 per share and not greater than $15.00 per share. Since the acquisition of PDP and the intent to launch the Tender Offer was announced on March 13, 2024, the average trading price of the Company's shares has surpassed the highest end of the Tender Offer range indicated, with the most recent closing price of the shares 11-21% above the range, and the Board believes the proposed Tender Offer would only receive limited participation. The Board has determined that launching a tender offer estimated to receive only limited participation would not achieve the Company's objectives while at the same time creating significant and unneeded costs for the Company that are not in the best interests of investors. In its continued effort to evaluate capital allocation priorities, the Board has determined that the best course of action to continue to return capital to shareholders is to increase the Company's share repurchase program by $30 million. Under the revised share repurchase authorization, the Company is authorized to acquire up to a total of $55 million of shares of its common stock, including the $8.4 million already acquired under the program, at its discretion from time to time in the open market, or in block purchases or privately negotiated transactions, subject to compliance with the applicable restrictions in the Company's debt agreements. The current balance remaining for the repurchase program, including today's increased authorization, is $46.6 million."

16:18 EDT Cal Water secures $83M in additional state funding for past-due balances - With financial impacts of COVID-19 felt by California Water Service, or Cal Water, customers well past the height of the pandemic, Cal Water applied for and has received more than $83M through the California Extended Water and Wastewater Arrearage Payment Program to relieve residential and commercial customers of past-due balances incurred during the pandemic. The Extended Program, administered by the State Water Resources Control Board, enables water suppliers to apply for financial support on behalf of customers. Cal Water first secured more than $20.8M about two years ago through the original Water & Wastewater Arrearage Payment Program for past-due balances incurred by residential and commercial customers between March 4, 2020, and June 15, 2021. Through the Extended Program, past-due debt incurred between June 16, 2021, and December 31, 2022, became eligible.

16:16 EDT Intrepid Potash announces accident involving CEO Bob Jornayvaz - Intrepid Potash announced that on Saturday, April 6, 2024, Bob Jornayvaz was involved in an accident while playing in the U.S. Open Polo Championship and is currently receiving treatment. The company said it would provide updates as more information becomes available.

16:15 EDT RCI Hospitality repurchased 27,265 common shares for $1.5M in Q2 - RCI Hospitality Holdings anticipates the closing in April of a $20.0M, 8.25% fixed rate, 10-year commercial bank loan, with a 20-year amortization schedule. The loan, expected to be secured by nine real estate properties appraised at $31.6M, would provide additional funds for working capital, at favorable commercial bank rates and terms. During Q2, RCI repurchased 27,265 common shares for $1.5M or an average of $56.12 per share, bringing the 6M24 total to 65,219 repurchased shares for $3.6M or an average of $55.23 per share. RCI had $13.0M in remaining repurchase authorization at March 31.

16:12 EDT RCI Hospitality reports Q2 sales for Nightclubs and Bombshells up 1.3% - RCI Hospitality Holdings reported sales for its Nightclubs and Bombshells restaurants for the Q2 of $71.7M, an increase of 1.3% or $900,000 compared to the year-ago period. Sales do not include non-core operations and are subject to final closing. Full Q2 financial results are expected by May 9. Eric Langan, President & CEO of RCI, said: "During 2Q24, increases in sales from last year's acquisitions and new locations more than offset year-over-year declines in same-store sales and from clubs in transition. While we continue to work at improving SSS, we have made noticeable progress with our development schedule, acquisitions, capital management, and share buybacks." Nightclubs sales totaled $59.0M, an increase of 4.2% or $2.4M year-over-year. Q2 reflected increases of $7.4M from acquisitions not in SSS. 2Q24 also reflected declines of 5.7% or $2.9M in SSS and of $2.1M from clubs reopened, reformatted or closed during or prior to the quarter. Sales totaled $12.8M, a decline of 10.4% or $1.5M year-over-year. Q2 reflected increases of $1.2M from locations not in SSS: Cherry Creek Food Hall in Greenwood Village with its Bombshells Kitchen, Bombshells San Antonio, and Bombshells Stafford. Q2 also reflected declines of 20.5% or $2.7M in SSS. Bombshells didn't start implementing previously announced management and marketing changes and cost cutting until mid-February 2024.

16:11 EDT Illumina names Jakob Wedel as Chief Strategy and Corporate Development Officer - Jakob Wedel has been named Chief Strategy and Corporate Development Officer. Wedel joined Illumina in November 2023 as CEO Chief of Staff, leading strategic transformation initiatives. In his new role, Wedel is responsible for driving Illumina's strategic planning, partnerships, and acquisitions. Previously, Wedel was partner at EY's strategy practice, co-leading their global life science practice, and served in roles at McKinsey & Company and Bain & Company. In the early 2000s, Wedel co-founded the Nordic strategy firm QVARTZ, which was later acquired by Bain.

16:10 EDT Beauty Health names Sheri Lewis chief supply chain and operations officer - The Beauty Health Company announced that it has appointed Sheri Lewis as Chief Supply Chain and Operations Officer, effective immediately. Lewis will report to BeautyHealth's President and Chief Executive Officer, Marla Beck. "Sheri is a talented and deeply experienced executive who brings decades of valuable global operations expertise to BeautyHealth as we chart the future of the Company," said Marla Beck, BeautyHealth President and Chief Executive Officer. "The Board of Directors and I are confident that her deep industry experience across global supply chain and operations will play a critical role in advancing our strategic objectives with the goal of further enhancing shareholder value." Before joining BeautyHealth, Ms. Lewis established herself as an industry leader in the areas of global supply chain and manufacturing operations. Most recently, Ms. Lewis was the EVP of global supply chain operations at Avantor, Inc., where she served on the executive committee and led the company's global integrated supply chain strategy and operational performance with oversight of over 3,500 associates.

16:09 EDT Virtus Investment reports March-end AUM $179.3B - Virtus Investment Partners "reported preliminary assets under management of $179.3 billion as of March 31, 2024. The increase from December 31, 2023 primarily reflects market performance and net inflows in retail separate accounts, partially offset by net outflows in institutional accounts and open-end funds. In addition, the company provided services to $2.7 billion of other fee-earning assets, which are not included in assets under management."

16:09 EDT Illumina names Ankur Dhingra as CFO, succeeding Joydeep Goswami - Illumina (ILMN) announced that CFO Joydeep Goswami has decided to leave Illumina. He will stay on in an advisory role through June 30 to support two new executive management team appointments. Ankur Dhingra is joining Illumina as CFO, leading Illumina's financial planning and analysis, accounting, investor relations, internal audit, tax, and treasury functions. Dhingra brings a breadth of experience from the life sciences tools, diagnostics, and pharmaceutical industries. He formerly was CFO at Summit Therapeutics (SMMT).

16:08 EDT Honest Company founder Jessica Alba to depart role as Chief Creative Officer - The Honest Company recently reported record quarterly sales and profits for Q4 of 2023, along with an updated long-term growth vision. With this growth vision in place and a strengthened business model, the company's founder Jessica Alba has determined that now is the right time to depart from her role as Chief Creative Officer, allowing her to shift her creative energy to new endeavors. She continues to provide her support and leadership as a member of Honest's board.

16:06 EDT Corvus initiates placebo-controlled phase 1 soquelitinib clinical trial - Corvus Pharmaceuticals announced the initiation of the Company's randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial is expected to enroll 64 patients at 12 sites in the United States, with the potential for initial clinical data before year-end 2024. "The initiation of our Phase 1 atopic dermatitis trial is an important step towards unlocking the broad potential of ITK inhibition for immune diseases," said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. "Soquelitinib has the potential to improve the treatment landscape for atopic dermatitis by providing an oral medication designed to block multiple cytokines involved in the inflammatory process, compared to current injectable biologic therapies that only inhibit one or a limited number of cytokines. We look forward to ramping up enrollment with the potential to share initial data from the trial before year-end, while also working to initiate our soquelitinib registrational Phase 3 trial for PTCL."

16:05 EDT Medigus announces corporate rebranding to Xylo Technologies - Medigus announced a corporate rebranding to reflect current focus in innovation technologies. At the heart of this rebranding is a change of the company's name to Xylo Technologies Ltd. to embody its corporate vision and core values. The rebranding includes a new name and an update to the company's corporate logo, as well as a new website. In addition, the company's Nasdaq trading symbols will change to XYLO. The company will begin trading on the Nasdaq Capital Market under its new name "Xylo Technologies Ltd." and new trading symbol "XYLO" upon the opening of the market on April 18.

16:02 EDT PriceSmart announces one-time special dividend of $1.00 per share - The Company has decided to distribute excess cash to stockholders in the form of a special dividend. On April 3, the company's Board of Directors declared a one-time $1.00 per share special dividend payable on April 30 to stockholders of record on April 19.

15:45 EDT Vimeo strength attributed to mention of rumor in Betaville blog - Shares of Vimeo are up 17c, or nearly 5%, to $3.87, which traders tell The Fly may be linked to a mention of a rumor related to the company by Ben Harrington's Betaville blog.

14:09 EDT Intel announces enterprise AI with Gaudi 3, AI open systems strategy - At the Intel Vision 2024 customer and partner conference, Intel (INTC) introduced the Intel Gaudi 3 accelerator to bring performance, openness and choice to enterprise generative AI, or GenAI, and unveiled a suite of new open scalable systems, next-gen products and strategic collaborations to accelerate GenAI adoption. With only 10% of enterprises successfully moving GenAI projects into production last year, Intel's latest offerings address the challenges businesses face in scaling AI initiatives. The Intel Gaudi 3 AI accelerator will power AI systems with up to tens of thousands of accelerators connected through the common standard of Ethernet. Intel Gaudi 3 promises 4-times more AI compute for BF16 and a 1.5-times increase in memory bandwidth over its predecessor. In comparison to Nvidia (NVDA) H100, the company said, Intel Gaudi 3 is projected to deliver 50% faster time-to-train on average across Llama models with 7B and 13B parameters, and GPT-3 175B parameter model. Additionally, Intel Gaudi 3 accelerator inference throughput is projected to outperform the H100 by 50% on average1 and 40% for inference power-efficiency averaged2 across Llama 7B and 70B parameters, and Falcon 180B parameter models. Intel Gaudi 3 will be available to OEMs - including Dell Technologies (DELL), HPE (HPE), Lenovo (LNVGY) and Supermicro (SMCI) - in the second quarter of 2024. Intel also outlined its strategy for open scalable AI systems, including hardware, software, frameworks and tools. Intel's approach enables a broad, open ecosystem of AI players to offer solutions that satisfy enterprise-specific GenAI needs. This includes equipment manufacturers, database providers, systems integrators, software and service providers, and others. It also allows enterprises to use the ecosystem partners and solutions that they already know and trust. Additionally, Intel announced collaborations with Google Cloud (GOOGL), Thales and Cohesity to leverage Intel's confidential computing capabilities in their cloud instances. Reference Link

13:50 EDT Better Choice Company trading halted, volatility trading pause

13:32 EDT HII awarded $74M contract to support U.S. Navy vertical launch systems - HII announced that its Mission Technologies division was awarded a $74M contract to research, analyze and develop enhanced capabilities for the Mk 41 and Mk 57 vertical launching systems onboard U.S. Navy surface ships. The task order, administered by the Naval Surface Warfare Center Port Hueneme Division, also applies to associated naval surface weapon systems, combat systems and sensors employed within the Navy. HII's statement of work includes outfitting the first Zumwalt-class destroyer with the latest Mk 57 vertical launch system universal canister electronics unit. "We are extremely pleased to continue our support to the U.S. Navy, providing critical research, development, test and evaluation in support of vertical launch systems for NSWC Port Hueneme," said Todd Gentry, president of Mission Technologies' C5ISR business group. HII was awarded the recompeted task order under the Department of Defense's Information Analysis Center Multiple Award Contract vehicle. The task order has a five-year term. Most of the work will be performed in Syracuse, New York, and Arlington, Virginia.

13:25 EDT Surrozen Inc trading halted, volatility trading pause

12:44 EDT Rent the Runway trading resumes

12:32 EDT Beamr Imaging Ltd trading resumes

12:16 EDT Medicenna Therapeutics presents preclinical data on MDNA113 - Medicenna Therapeutics announced new preclinical data on MDNA113, the Company's novel T-MASK candidate, an IL-13Ra2 specific superkine featuring unique masking and tumor targeting characteristics, were presented at the 2024 Annual Meeting of the American Association for Cancer Research held in San Diego, CA, on April 9th, 2024. The Company selected MDNA113, a novel, first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL-2 superkine with high selectivity and affinity for IL-13Ra2, a tumor associated antigen expressed in many aggressive solid tumors. The IL-13 Superkine is a highly specific tumor-targeting/masking domain which is fused via a protease sensitive linker to a bi-functional immunotherapy domain containing an IL-2 Superkine fused to an anti-PD1 antibody. Key findings presented at the conference include: When not activated, MDNA113 shows reduced IL-2R agonism with no change to PD-1/PDL-1 blockade activity. Cleavage and activation of MDNA113 by cancer specific enzymes releases the T-MASK domain, restoring activity of the IL-2 Superkine at the tumor site. MDNA113 shows attenuated systemic lymphocyte expansion compared to non-masked version, consistent with design of MDNA113. MDNA113 is better tolerated than non-masked counterpart, supporting higher and more efficacious dosing schedule. MDNA113 selectively binds IL-13Ra2 positive tumor cells in vitro, and durably accumulates in IL-13Ra2 positive tumors in mice. Cleavable MDNA113 shows similar efficacy as non-masked MDNA223 in mouse tumor models by either localized or systemic delivery, consistent with proteolytic activation within TME. Single neoadjuvant treatment with MDNA113 in a highly invasive orthotopic 4T1.2 breast cancer model significantly increases survival by preventing metastasis. In summary, the T-MASK platform exemplified by MDNA113, facilitates tumor targeting and minimizes systemic toxicity while maximizing therapeutic activity at the tumor site.

12:12 EDT Beamr Imaging Ltd trading halted, volatility trading pause

12:11 EDT Compass Therapeutics presents data on combination of CTX-009, CTX-471 - Compass Therapeutics presents a poster on the combination of its bispecific antibody, CTX-009, and its agonistic anti-CD137 antibody, CTX-471, on anti-tumor activity in preclinical models at the 2024 American Association for Cancer Research Annual Meeting taking place at the San Diego Convention Center in San Diego, California on April 9. Data highlights from the poster presentation include: The combination of mCTX-009 and mCTX-471 demonstrated superior efficacy in both Checkpoint Inhibitor-sensitive and CPI-refractory models with markedly enhanced anti-tumor activity compared with either monotherapy. Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors. Deletion of B2m produced MHC-I null phenotypes in two colorectal cancer cell lines. Tumor elimination was in part mediated by NK cells. These preclinical data suggest that the combination of CTX-009 and CTX-471 could re-establish anti-tumor immunity in patients whose tumors have either downregulated or lost MHC-I expression by way of NK-cell mediated tumor cell killing.

12:06 EDT Immuneering presents preclinical data on IMM-1-104 at AACR 2024 - Immuneering Corporation presented preclinical data at the American Association for Cancer Research Annual Meeting, which the company views as supportive of its ongoing Phase 2a clinical trial of IMM-1-104 in RAS-mutated advanced or metastatic solid tumors. In a poster titled, "Activity of IMM-1-104 alone or in combination with chemotherapy in RAS-altered pancreatic cancer models," IMM-1-104, gemcitabine, nab-paclitaxel, and 5-fluorouracil were evaluated in tumor xenograft models alone or across multiple combinations. Results: IMM-1-104 showed promising combination effects when treated with gemcitabine, paclitaxel or fluorouracil in 3D-tumor growth assay pancreatic cancer models. IMM-1-104 was synergistic with chemotherapy in animal models of pancreatic cancer. In a human pancreatic cancer cell line (MIA PaCa-2) tumor xenograft model, IMM-1-104 alone showed greater tumor growth inhibition and better durability than any single or combination chemotherapy tested. At day 39, antitumor activity was 103% for IMM-1-104 at 125 mg/kg BID PO, 25.2% for GEM at 60 mg/kg IP Q4D, 62.2% for PAC at 10 mg/kg IV Q4D, and 36.6% for 5FU at 50 mg/kg IP Q4D. In the Phase 2a portion of Immuneering's ongoing IMM-1-104 Phase 1/2a clinical trial, IMM-1-104 is being evaluated as both monotherapy and in select combinations with approved chemotherapeutic agents. The Phase 2a portion includes five arms, three of which focus on patients with pancreatic cancer. Patients are now on treatment in multiple arms of the ongoing Phase 2a trial, including multiple patients with pancreatic cancer who are being treated with IMM-1-104 in combination with chemotherapy in the first-line setting. The company expects initial data from multiple Phase 2a arms in 2024.

12:02 EDT Atossa Therapeutics presents data from 40mg cohort of Phase 2 EVANGELINE trial - Atossa Therapeutics announced promising safety and efficacy data from the Company's Phase 2 EVANGELINE clinical trial. The EVANGELINE study is evaluating (Z)-endoxifen as a neoadjuvant treatment for pre-menopausal women with Grade 1 or 2 Estrogen Receptor positive/ Human Epidermal Growth Factor Receptor 2 negative breast cancer. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. The data, which is being presented at the American Association for Cancer Research Annual Meeting, is from the 40mg pharmacokinetic run-in cohort of the study. Seven women were enrolled in the cohort and treated daily for 28 days. At 28 days, six of the seven had Ki-67 levels below 10% and stayed on treatment for an additional five months. Per the study protocol, the seventh patient, whose Ki-67 decreased 19% but stayed above 10%, discontinued treatment and had surgery. Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging central review demonstrated target lesion decreases in all patients with one complete response, one partial response and four stable disease, per Response Evaluation Criteria In Solid Tumors criteria. The average target lesion decrease was 32% at 12 weeks and 37% at 24 weeks with all patients experiencing at least a 15% reduction in target lesion at 24-weeks. Ki-67 for the 40mg cohort patients was reduced from an average of 14.5% at screening to 5.3% at 28 days and 1.2% at 24-weeks. This represents a reduction of 63% at 28 days and 92% at 24 weeks. Ki-67 is a cellular marker for proliferation and indicates how fast the tumor is growing. Less than 10% is considered low and associated with better surgical outcomes and a lower incidence of recurrence. Treatment related toxicities included grade 3 headache, grade 2 amenorrhea and grade 2 hot flashes. There were no grade 4 or 5 treatment related toxicities.

12:00 EDT Cava Group falls -8.1% - Cava Group is down -8.1%, or -$5.28 to $59.66.

12:00 EDT XPeng rises 8.3% - XPeng is up 8.3%, or 61c to $8.00.

12:00 EDT OppFi rises 22.7% - OppFi is up 22.7%, or 58c to $3.14.

11:27 EDT SUUN Stock trading halted, volatility trading pause

11:03 EDT Wyndham Hotels & Resorts appoints Scott Strickland as CCO - Wyndham Hotels & Resorts appointed Scott Strickland Chief Commercial Officer reporting to the company's President and CEO, Geoff Ballotti. In this newly created leadership role, Strickland and his team will continue delivering the best value and experiences to Wyndham's owners and guests across its 25 brands through a united commercial organization. As Chief Commercial Officer, Strickland continues his responsibilities for enhancing and implementing Wyndham's technology and distribution strategy and will add oversight of global sales; revenue generation; marketing; communications and the award-winning loyalty program, Wyndham Rewards. With the creation of this new organization, Lisa Checchio, EVP and Chief Marketing Officer, will depart Wyndham Hotels & Resorts.

10:16 EDT Transcat says Mark Doheny to step down as COO effective immediately - Transcat announced that Mark Doheny will step down as COO of Transcat effective immediately. Doheny will be retained as a consultant to assist with a transition through October 2024. The company announced the promotion and appointment of Mike West, current Senior Vice President of Operations, to replace Doheny. "As we enter the next chapter of Transcat's growth, I believe it is the right time to transition operations leadership," said Lee Rudow, CEO and President.

10:05 EDT Textron announces enhanced Cessna aircraft enter into service - Textron Aviation announced the entry into service of its enhanced Cessna Skyhawk, Cessna Skylane, Turbo Skylane and Turbo Stationair HD following first deliveries for each aircraft. These latest product investments aim to provide a modern and stylish tone that aligns with the newest Cessna Citation jets, while maintaining the renowned comfort, durability and performance of the iconic Cessna piston lineup.

10:03 EDT Sinclair Broadcast begins generative AI usage - Sinclair announced the company has taken its first steps into usage of generative artificial intelligence within its original content to reach more audiences globally in their native languages. Sinclair will begin using AI for language translation beginning with "Petko Unfiltered," a Tennis Channel series with network analyst Andrea Petkovic, a former WTA world #9 player. "Petko Unfiltered" provides an in-depth and unfiltered first-person perspective on trending tennis topics. The episodes, which are recorded and presented by Tennis Channel in English in several European countries and on its second network T2 in the United States, will be translated into Spanish to air on Tennis Channel in Spain beginning later this month . For this initiative, Sinclair has collaborated with HeyGen, a leading generative AI video company, specializing in voice translation and lip-sync services, transforming the way businesses use video to enable global storytelling.

10:02 EDT Datasea CEO intends to purchase $3M of common stock over next 12 months - Datasea announced that Zhixin Liu, Founder and CEO of company, intends to purchase up to $3M of the company's common stock from time to time from her personal funds over the next 12 months. Such purchases will be executed on the open market at prevailing market prices, and CEO Zhixin Liu has sole discretion as to how much Datasea common stock she will purchase, up to a $3M limitation. CEO Zhixin Liu currently holds a 25.08% position of the common stock, which represents the largest ownership position of the company's shares.

10:00 EDT Kenon falls -4.3% - Kenon is down -4.3%, or -95c to $20.92.

10:00 EDT Mytheresa falls -5.3% - Mytheresa is down -5.3%, or -20c to $3.50.

10:00 EDT Pitney Bowes rises 9.4% - Pitney Bowes is up 9.4%, or 37c to $4.29.

09:47 EDT Kenon falls -2.6% - Kenon is down -2.6%, or -56c to $21.31.

09:47 EDT X Financial falls -6.6% - X Financial is down -6.6%, or -26c to $3.70.

09:47 EDT Sibanye Stillwater rises 7.3% - Sibanye Stillwater is up 7.3%, or 40c to $5.91.

09:41 EDT Dogness Internationa trading resumes

09:38 EDT DXYZ Stock trading resumes

09:35 EDT Lithium Corp. expands portfolio with fluorspar property - Lithium Corporation informed investors the Company recently expanded its portfolio with the addition of a newly staked property prospective for hosting fluorspar mineralization. The Las Pilas claim block, staked by Lithium Corp. in February 2024, is located in the Greenwood Mining Division in south central British Columbia, Canada. The approximately 5,178 acre property lies roughly three kilometers from the past producing Rock Candy Fluorspar mine. The mine produced around 51,500 tonnes of ore with an average grade of 68% CaF2, 22% SiO2 between 1918 and 1929. It closed during the Great Depression and never reopened. Another 60,000 tonnes of probable ore is estimated contained in the previously mined workings. While fluorite epithermal vein mineralization is known to extend from this area more than a kilometer north to Fluorine Lake, no modern work has been conducted to expand the size of the deposit. Lithium Corporation's claim block was staked on the basis of similar geology, stream sediment and water geochemistry as seen in the vicinity of the Rock Candy Mine. The highest fluorine value in the general area was collected from a stream that drains northern portions of the Company's block. This is believed to be a strong indicator that similar or better mineralization occurs in the general area. The Company is excited about the potential of this prospective property, and anticipates commencing geochemical and geological surveys here within the month.

09:33 EDT DXYZ Stock trading halted, volatility trading pause

09:31 EDT Silynxcom wins order from German police department - Silynxcom received first-time orders for a German county police department for its new hearing-protective in-ear headset systems, designed for law enforcement organizations. One of the ways Silynxcom's advanced in-ear headset systems will be used by this police department is for the securing of a high-profile international sports event in Germany.

09:29 EDT BIO-key announces Canton of Ticino implements AuthControl Sentry solution - BIO-key announced that Switzerland's Canton of Ticino has partnered with Asecus AG to implement BIO-key's AuthControl Sentry login solution. In a significant enhancement to its digital security, Ticino's Information Systems Center has integrated AuthControl's advanced protection for Office365 login across their network. Ticino is the southernmost of Switzerland's 26 cantonsand the sole canton where Italian is the only official language.

09:25 EDT Scilex launches co-pay programs for ZTlido and ELYXYB - Scilex Holding Company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced launching of co-pay programs for both ZTlido( and ELYXYB with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0. This applies to the Company's postherpetic neuralgia pain product, ZTlido and migraine product, ELYXYB . Scilex has made significant investments to improve patient affordability and access to its products and continues to build on the Company's commitment to provide non-opioid pain management products to patients.

09:23 EDT Safety Shot, Nelk Boys partner for brand ambassadorship - Safety Shot announced that the Nelk Boys have joined forces with Safety Shot as brand ambassadors. The Nelk Boys are an entertainment and retail company with YouTube channels under brands including NELK and Full Send that feature prank videos and high profile guests like Elon Musk, Donald Trump, and Mike Tyson. The Nelk Boys have popularized and trademarked the term "Full Send" which they brand as FULL SEND to mean "any activity you do, give it your absolute best".

09:21 EDT Navigator Holdings announces first ship-to-ship transfer of ammonia - Navigator Holdings performed its first ship-to-ship transfer of ammonia. Following a long history of the safe and successful liquified gas ship-to-ship transfers, Navigator Gas reaches a significant milestone in completing its first ship-to-ship transfer of anhydrous ammonia. In a carefully planned and closely monitored operation lasting eleven hours, on April 3, 2024 Navigator Gas' vessel, the "NAVIGATOR JORF", a 38,000 cbm liquefied petroleum gas gas carrier, safely received 25,300 metric tonnes of NH3 from LPG tanker "ECO ORACLE", whilst moored alongside in the Port of Ngqura, South Africa. By showing that a ship-to-ship transfer of NH3 can be completed safely, reliably and efficiently, Navigator Gas expects this successful process will lead to future opportunities to utilise NH3 as an alternative fuel source and to facilitate the transition towards zero-emissions shipping.

09:20 EDT Cogent Biosciences presents preclinical data of CNS-penetrant ErbB2 inhibitor - Cogent Biosciences announced new preclinical data from the Company's potent, selective, CNS-penetrant ErbB2 inhibitor program. The data are being presented in a poster session at the American Association for Cancer Research 2024 Annual Meeting taking place in San Diego, California. Title: Characterization of a Novel Mutant Selective, EGFR Sparing, ErbB2 Inhibitor with Activity Across Activating Mutations in Systemic and CNS Tumors. Cogent is developing a potential best-in-class EGFR-sparing, brain-penetrant ErbB2 inhibitor that includes potent coverage of key mutations inadequately addressed by currently approved therapies. Activating mutations in the ErbB2 gene have been identified in multiple cancers and demonstrate a tumorigenic role similar to that of ErbB2 amplification. The poster presented today describes CGT4255's exceptional stability in human whole blood and liver cytosol fractions and high oral bioavailability and low clearance across preclinical species. In addition, CGT4255 demonstrated 80% brain penetrance in mice and was well-tolerated at 10x concentration, resulting in mouse tumor regression, suggesting potential best-in class properties.

09:18 EDT Synaptogenix increases stake in psilocybin drug discovery company - Synaptogenix has increased its stake in psilocybin drug discovery company PsygaBio through its partnership with Cannasoul Analytics. Synaptogenix acquired a 25% stake in Cannasoul during November 2023 in support of R&D for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Development Foundation, the commercialization arm of The Technion-Israel Institute of Technology. Cannasoul's subsidiary, PsygaBio, is engaged in mushroom cultivation, psilocybin extraction, and the exploration of active compounds and formulations for therapeutic benefits. Its initial therapeutic targets inflammatory and central nervous system disorders such as Alzheimer's disease, Parkinson's disease, inflammatory bowel disease, and ocular conditions. Synaptogenix, through its partnership with Cannasoul, expanded its stake in PsygaBio, enabling Synaptogenix Chairman Josh Silverman and Director Bruce Bernstein to join PsygaBio's board of directors. As of December 31, 2023, Synaptogenix reported a cash balance of $28.7M. Psilocybin was the highest revenue-grossing segment in the global psychedelic drugs market in 2023.

09:15 EDT Royal Gold provides update on Q1 stream segment sales - Royal Gold announced that its wholly owned subsidiary, RGLD Gold AG, sold approximately 49,500 gold equivalent ounces comprised of approximately 38,100 ounces of gold, 635,000 ounces of silver and 1,100 tonnes of copper related to its streaming agreements during the three-month period ended March 31, 2024. The Company had approximately 16,800 ounces of gold, 349,400 ounces of silver, and 400 tonnes of copper in inventory at March 31, 2024. RGLD Gold AG's average realized gold, silver and copper prices for the first quarter were $2,054 per ounce, $23.22 per ounce and $8,453 per tonne, respectively. Cost of sales was approximately $436 per GEO for the first quarter. Cost of sales is specific to the Company's streaming agreements and is the result of the Company's purchase of gold, silver or copper for cash payments at a set contractual price, or a percentage of the prevailing market price of gold, silver or copper when purchased.

09:13 EDT Comdata announces Chargepass goes contactless - Comdata launched a new contactless feature for its Chargepass Mastercard. The Chargepass solution aims to streamline the payment experience for businesses by simplifying spending and catering to their needs for public charging and mixed fleet fueling-now, with one tap!

09:12 EDT IGC Pharma adds Arbelaez as an advisor in Artificial Intelligence - IGC Pharma announces the addition of Pablo Arbelaez, Ph.D. Dr. Arbelaez will support the development of the Phase 2 clinical trial of IGC-AD1, IGC Pharma's lead therapeutic candidate targeting agitation in Alzheimer's disease. Recent interim results from the IGC-AD1 Phase 2 trial demonstrated a clinically and statistically significant reduction in agitation compared to placebo in patients with Alzheimer's disease, indicating strong therapeutic potential.

09:11 EDT C3.ai announces Murray has joined its board of directors - C3 AI announced that Alan Murray, CEO of Fortune Media, will join its board of directors, effective May 1, 2024. Murray brings a wealth of experience in business journalism, leadership, and corporate strategy to the board. In his role as a board member, Murray will collaborate closely with C3 AI's leadership team to provide strategic guidance as the company continues to grow and drive innovation in enterprise AI across industries.

09:11 EDT DuPont unveils Pyralux ML laminate series - DuPont introduced the DuPont Pyralux ML Series of double-sided metal-clad laminates, a unique addition to its extensive family of Pyralux laminates for flexible and rigid-flex printed circuit boards. Developed for optimal thermal management, these laminates are an ideal solution for high-reliability markets such as aerospace, defense, electric vehicles, artificial intelligence related networking and other electronic devices. The Pyralux ML laminate series provides exceptional performance in challenging environments, making it a versatile and innovative solution for many different applications. DuPont is exhibiting the innovative new laminates this week during IPC APEX Expo, April 9-11, at the Anaheim Convention Center.

09:10 EDT LQR House reports 370% y/y revenue growth in March - LQR House announces a 370% year-over-year increase in revenue for March 2024 compared to the corresponding period in 2023. In March 2023, the Company recorded revenues of $43,578.33, while March 2024 witnessed a substantial surge, with revenues reaching $206,221.82. Sean Dollinger, CEO of LQR House, expressed his enthusiasm over such performance, stating, "The numbers speak for themselves. A 370% increase in year-over-year revenue for March 2024 compared to March 2023 underscores our consistent growth. LQR House continues to forge new marketing partnerships, expanding both our alcohol e-commerce business and marketing campaigns for alcohol brands. We're immensely proud of the strides we're making every day, and these year-over-year increases reflect progress across all fronts."

09:09 EDT Dolphin Entertainment partners with Rachael Ray, Do Good Spirits - Rachael Ray announces her partnership with Dolphin Entertainment as the official creative marketing partner for Staple Gin, launching in May 2024 along with renowned distillery, Do Good Spirits. With a botanical recipe developed by Ray and then crafted in the heart of New York's Catskills region by Do Good Spirits Founder Brian Facquet, Staple Gin is distilled with juniper, coriander, orris root, Castelvetrano olives, dried bergamot peel, tarragon and extra virgin olive oil.

09:08 EDT enVVeno Medical appoints Andrew Cormack as CCO - enVVeno Medical Corporation announced that Andrew Cormack has been hired as the Company's Chief Commercial Officer. Mr. Cormack, who joined enVVeno Medical on April 8, comes to enVVeno following a career at both start-up and large medical device companies including WallabyPhenox, Medtronic, Covidien, and ev3.

09:07 EDT Seanergy Marine, United Maritime provide financial update - Seanergy Maritime Holdingsreported a fourth-quarter net profit of $10.8 million, a significant increase from $0.5 million in the previous year. The company's revenue also grew to $39.4 million compared to $28.5 million for the same quarter last year. Despite a very volatile Capesize market, Seanergy's daily time charter equivalent outperformed the Baltic Capesize Index by 7% in 2023. For the first three months of 2024, the company is projecting a TCE of $23,219 per day. During the full-year period, they recorded a net income of $2.3 million, while their fleet's average daily rate was $17,501, exceeding the Baltic Capesize Index average of $16,389. Seanergy says its consistent ability to generate higher revenues from its Capesize fleet compared to industry benchmarks sets it apart from other shipping companies like Hapag-Llyod Aktien and Matson Inc. In the first quarter, experiencing the strongest start for the Capesize market since 2011, Seanergy reports it has capitalized on the surge in freight futures prices. Seanergy has utilized the freight futures market to fix the rates for approximately half of its ownership days in the second quarter at around $28,300 per day, securing strong cash flow and profitability. In February 2024, Seanergy acquired a 2013 Japanese-built Capesize dry bulk vessel with a capacity of 181,392 deadweight tons, which will be renamed M/V Iconship. The purchase price was $33.7 million, however, the value of the bulker has increased to $38 million since. Seanergy's spin-off company, United Maritime Corporation completed a sale-and-leaseback transaction to generate liquidity and potentially expand its fleet of bulkers. The transaction allowed United Maritime to refinance an existing $13 million loan facility. The six-year lease gives United Maritime options to repurchase the vessel after the first two years, with ownership transferred at no additional cost. In 2023, United Maritime successfully regrew its fleet, continuing the shareholders' reward program, and managed to record a positive bottom line. The net revenues for 2023 were $36.1 million, which increased by 58% compared to 2022, but so did voyage expenses, interest and finance costs. As a result, their fleet earned an average daily TCE rate of about $15,400 in 2023, compared to $28,800 in 2022. United Maritime recorded $11.6 million in net revenues, with adjusted EBITDA at $4.6 million for the fourth quarter. Despite the quarterly loss of $0.7 million, United Maritime maintained the dividend of $0.075 per share, reflecting a solid 11% annualized yield. United Maritime anticipates that the fleet's daily TCE earnings could see additional growth if the physical market aligns with the forward curve for freight rates this quarter. Furthermore, it is securing higher rates for some of the ownership days in the second quarter compared to those achieved in the first quarter

09:06 EDT Range Energy, Thermo King enter collaboration - Range Energy, the hardware company bringing powered trailers to the commercial trucking market, and Thermo King, a Trane Technologies brand, announced a strategic collaboration to advance the commercialization of electric refrigerated trailers. "Thermo King's commitment to sustainability and decarbonization is only matched by our drive to provide customers with the solutions they need. With that comes integrating innovative technologies, like Range's electric trailer platform, that can help us deliver more efficient and reliable transportation solutions while keeping transported food and perishables safe and fresh," said Paul Kroes, senior trailer product manager, Thermo King. "Range is an early mover in trailer electrification, and we're confident our partnership can accelerate our industry's decarbonization efforts."

09:05 EDT Gaucho Group announces measures to streamline operations, cost efficiencies - Gaucho Group announced a series of strategic measures to streamline operations and cost efficiencies. These efforts are expected to yield approximately $1.5 million in expense savings over the next 12 months, with the anticipation of up to an additional $1 million in expenses saved in 2025. By eliminating certain functions and offshoring others to its offices in Argentina, the Company aims to capitalize on the cost-effective labor and specialized skills available in the region. Furthermore, the savings accrued from these strategic initiatives are planned to be allocated towards marketing expenses, aiming to promote its portfolio of brands, including Gaucho - Buenos Aires and Maison Gaucho, Algodon Fine Wines, Algodon Wine Estates, and its hospitality projects. This restructuring is not just about cost-saving; it represents a strategic pivot towards maximizing the potential of Gaucho Holdings' operations in Argentina, particularly in the realm of luxury real estate. The Company is poised to recognize revenue from the deeding of real estate projects in 2025, with a primary focus on the vineyard estate lots at Algodon Wine Estates in San Rafael, Mendoza, Argentina. To date, approximately 15% of the total lots have been sold, leaving significant room for future sales and development. The potential revenue from these sales, coupled with interest income from the Company's self-financing options to buyers, is expected to significantly enhance financial results in the coming years. Furthermore, Gaucho Holdings is closely monitoring the evolving economic landscape in Argentina, particularly the potential adoption of the USD as the country's primary currency. This shift, championed by President Milei, could drastically change the dynamics of the real estate market by enabling leverage through bank lending, a move that could significantly boost real estate values across the nation. This transition to a more stable currency for transactions could unveil substantial growth opportunities for Gaucho Holdings' real estate assets.

09:03 EDT Cadrenal Therapeutics confirms FDA orphan designation for tecarfarin - Cadrenal Therapeutics announced that the United States FDA has granted tecarfarin Orphan Drug Designation for the prevention of thromboembolism and thrombosis in patients with an implanted mechanical circulatory support device, right ventricular assist device, collectively known as ventricular assist devices, biventricular assist device, and total artificial heart.

09:01 EDT Lucid Group reports vehicle production of 1,728 in Q1 - Delivered 1,967 vehicles in Q1.

08:58 EDT Stronghold mined 179 Bitcoin in March, turned off Scrubgrass plant - Stronghold Digital Mining y provided the following updates regarding its operations and financial performance: Stronghold mined 179 Bitcoin in March 2024 and generated approximately $0.1M in energy revenue, which represents the equivalent of approximately one additional Bitcoin based on the average price of Bitcoin during the month. This equates to approximately 180 of Bitcoin-equivalent production in March 2024, up approximately 4% from 173 Bitcoin-equivalent production in February 2024. The Company generated an estimated $11.1M of revenue during March, an increase of 37% and 94% compared to February 2024 and March 2023, respectively. The primary driver of the sequential increase was a higher hash price of $0.109 per TH/s per day in March compared to $0.084 in February, which was due to a 35.8% higher Bitcoin price, partially offset by lower transaction fees, averaging 4.6% in March compared to 5.5% in February, and 4.3% sequential growth in network hash rate. Stronghold's average hash rate improved to 3.6 EH/s in March, up 4.7% compared to its average hash rate of 3.4 EH/s in February, and up 62.6% from the average hash rate of 2.2 EH/s in March 2023, and an increased average hash price of $0.109 in March 2024 compared to $0.073 in March 2023. In March 2024, due to continuing low power prices and the company's expectation that they will persist through the coming shoulder months, the Company elected to turn off its Scrubgrass Plant and to instead import electricity for its mining operations pursuant to its previously announced Electricity Sales and Purchase Agreement with Champion Energy Services..The Scrubgrass Plant is expected to remain off until it becomes economically compelling to run it relative to purchasing electricity.

08:57 EDT ASP Isotopes enters warrant inducement transaction for $5.5M in gross proceeds - ASP Isotopes has entered into an agreement with an institutional investor that is an existing holder of warrants to purchase shares of common stock of the Company for cash wherein the investor agreed to exercise the Existing Warrants to purchase the maximum of 3,164,557 shares of common stock at an exercise price of $1.75 per share, resulting in gross proceeds of approximately $5.5 million, before deducting offering expenses. In consideration for the exercise of the Existing Warrants for cash, the exercising holder will receive new warrants to purchase up to an aggregate of 1,225,000 shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended. The Company believes the structure of this transaction will result in substantially less fees, costs and dilution than may occur in other capital raising transactions, such as an underwritten offering of common stock or a private placement priced at a discount. "We took the opportunity to do this transaction because we view it as an attractive means of raising additional capital; $5.5 million for 1.225 million new warrants is effectively $4.50 per share with minimal transaction costs," said Paul Mann, Chairman and CEO of ASP Isotopes. The offering is expected to close on or about April 11, 2024. The New Warrants will be exercisable on and after the date that is six months following the date of issuance at an exercise price of $3.90 per share and will expire on the five year anniversary of their initial exercise date.

08:55 EDT ExlService partners with Quilt.AI for customer insight - EXL announced a partnership with Quilt.AI. This collaboration aims to merge EXL's deep data, AI and industry expertise with Quilt.AI's advanced AI-powered platform, which transforms big data into human insights and cultural understanding. The partnership will utilize the combined capabilities of both companies to help clients in industries such as retail, consumer packaged goods, financial services, and insurance to discover industry and product trends, analyze consumer journeys, and gauge consumer sentiment quickly and accurately. EXL intends to expand its ability to help clients understand their data and gain deeper insights into the contexts that shape consumer behaviors and preferences through proprietary AI models. This will enable businesses to make more informed decisions, proactively respond to changing market dynamics, and offer superior customer experiences.

08:53 EDT Runway Growth Finance funded two investments in Q1 - Runway Growth Finance provided an operational and portfolio update for the first quarter ended March 31, 2024. In the first quarter of 2024, Runway Growth funded two investments: one investment in a new portfolio company and one investment in an existing portfolio company. These include: Completion of a $32.0 million investment to a new portfolio company in the automotive technology industry that provides real-time enterprise software solutions to help dealers elevate the car-buying experience by transforming the way they connect with customers, funding $20.0 million at transaction close; and completion of a $5.0 million follow-on investment to Madison Reed, consisting of a $1.2 million delayed draw and $3.8 million upsize to its existing commitment. Madison Reed is a digitally enabled prestige hair color company predominantly focused on women. During the first quarter ended March 31, 2024, Runway Growth experienced two prepayments totaling $34.5 million and scheduled principal amortization of $0.4 million. The prepayments include: Partial principal repayment of the Company's senior secured term loan to FiscalNote of $27.4 million; and Partial principal repayment of the Company's senior secured term loan to Marley Spoon Group of $7.1 million.

08:50 EDT Cemtrex's Vicon Industries to attend ISC West 2024 - Cemtrex announced that its subsidiary, Vicon Industries, is set to showcase its new AI-powered unified cloud solution at ISC West 2024, which will be held April 9-12, 2024 at the Venetian Expo, Las Vegas, and with be exhibiting at booth #26049. The Vicon exhibit will focus on the company's innovative new cloud security platform-Anavio-which lets users manage their access control, video, and intercom via a single tool, so there's no shuffling between separate security systems in order to achieve complete situational awareness and control. Plus, Anavio's remote monitoring and management capabilities allow security operations to be performed from anywhere, via any smart device. And because it's cloud-based, there's no extensive on-prem hardware to set up, configure, or maintain. This means customers can invest in the solution and the technology, not the burden of deploying and managing it.

08:49 EDT Nexalin Technology accelerates manufacturing of HALO Clarity - Nexalin Technology has completed the first full production test run and successfully performed usability, feasibility design verification, and electrical safety testing for its new Gen-3 HALO Clarity 15 milliamp neurostimulation device in the U.S. As a result, the Company is now ramping up manufacturing in advance of its planned clinical trials and expects to produce approximately 500 units in the third quarter of 2024. Nexalin plans to conduct clinical trials of the HALO Clarity in the U.S. and is in the process of consulting with the U.S. Food and Drug Administration as part of its pre-submission meetings. The Company expects that its upcoming clinical trials will be completed in an expedited timeframe and at a considerably lower expense, since the HALO Clarity treatment can be administered at home - as opposed to a hospital or outpatient clinical setting - and the resulting data can be captured and patient response can be contemporaneously transmitted electronically. Contingent upon FDA approval, the home-use aspect of HALO Clarity is expected to significantly reduce patient treatment costs, while increasing compliance with applicable standards.

08:47 EDT Bridgeline Digital says Schaedler Yesco launches HawkSearch implementation - Bridgeline Digital announced Schaedler Yesco Distribution has implemented Bridgeline's HawkSearch on its Optimizely powered eCommerce site using the Xngage Connector for HawkSearch. HawkSearch will enhance Schaedler Yesco's eCommerce strategy by offering precise search tailored to electrical industry professionals. This includes advanced part number search functionality for both full and partial numbers, unit of measurement conversion, and merchandising tools to run product-specific campaigns.

08:44 EDT IM Cannabis partners with Vessel Cannabis for cannabis accessories in Israel - IM Cannabis entered, through its subsidiary, a strategic distribution agreement with Vessel Brand, a subsidiary of Flora Growth, a global consumer-packaged goods leader and pharmaceutical distributor, headquartered in Carlsbad, CA. Vessel is a premium cannabis accessories brand with a range of products.

08:43 EDT Verizon implements Managed SD WAN for Commonwealth of Virginia - Verizon has successfully implemented Managed Software Defined Wide Area Networking to about 1,000 sites for the Commonwealth of Virginia. This milestone accomplishment is a result of the partnership between Verizon and the Commonwealth, where the focus is on further enabling digital government through enhanced network performance.

08:42 EDT Cardio Diagnostics partners with Exponential Health - Exponential Health is set to offer Cardio Diagnostics Holdings' clinical epigenetic-genetic cardiovascular tests, Epi+Gen CHD and PrecisionCHD, to their patients. As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease. "We are thrilled to partner with Dr. Baer and Exponential Health," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics. "This partnership is a powerful demonstration of our shared commitment to advancing cardiovascular health through innovation. By integrating our precision medicine solutions into Exponential Health's practice, we are poised to make a significant impact on preventing heart disease and improving outcomes for patients."

08:41 EDT LM Funding mines 27.9 bitcoin in March - Bruce M. Rodgers, Chairman and CEO of LM Funding, stated, "Our mining operations continued to deliver solid results in March 2024. We mined enough Bitcoin in excess of operating expenses and were able to pay the purchase price balance owed on our recently acquired Bitmain S21 Antminer machines. As we approach the Bitcoin halving event, expected to occur later this month, we expect to be entering into new hosting agreements reflecting post-halving economic realities and will continue to evaluate additional purchases of Antminer machines to drive our further growth." The Company estimates the value of its 163.4 Bitcoin holdings at March 31, 2024, was approximately $11.7 million, based on an estimated April 8, 2024, BTC price of $71,500.

08:39 EDT Microchip launches AVR-DU family of microcontrollers - The company said, "The well-known advantages of a Universal Serial Bus interface for embedded designs include its compatibility with various devices, streamlined communication protocol, in-field updatability and power delivery capabilities. To help easily incorporate this functionality into embedded systems, Microchip Technology has launched the AVR DU family of microcontrollers. As the next generation of Microchip 8-bit MCUs to integrate USB connectivity, the AVR DU family is designed to provide enhanced security features and higher power delivery than previous iterations."

08:38 EDT Clearmind CEO says poised to achieve 'significant milestones' through 2024 - Clearmind Medicine provided the following letter to shareholders from the Company's CEO, Dr. Adi Zuloff-Shani: "In 2023, Clearmind made significant advances on its groundbreaking journey, propelling our flagship compound, CMND-100, through critical stages with a goal of revolutionizing the treatment of alcohol use disorder as well as other addictive disorders and mental health conditions. Recently, our efforts reached a key inflection point as the Israeli Ministry of Health approved our Phase I/IIa clinical trial for CMND-100 for AUD. CMND-100, a pioneering MEAI-based formula, has exhibited encouraging results in pre-clinical studies. Notably, it has shown the ability to disrupt the destructive cycle of binge drinking without inducing hallucinations-a common concern with existing treatments. This distinction is vital as it ensures both safety and efficacy in addressing AUD. It uniquely targets the neural pathways to reduce impulsivity and promote reasoned behavior, positioning it as an innovative solution in the battle against addictions. 2023 was marked by an array of significant milestones aimed at initiating our Phase I/IIa clinical trial of CMND-100 in AUD, including: Completing Type A meeting with the FDA. Forming a Data and Safety Monitoring Board for oversight of our first-in-human clinical trial; Strengthening our clinical trial readiness through key partnerships for manufacturing and contract research organization support. Securing IRB Approval for our Phase I/IIa clinical trial in Israel, a critical step towards our clinical endeavors. Announcing Johns Hopkins University and Yale School of Medicine's Department of Psychiatry as the first U.S. sites for our Phase I/IIa clinical trial. Other key developments during the year, included: Unveiling promising pre-clinical outcomes in obesity and metabolic disorders, suggesting MEAI may be a potentially better and safer option compared to other weight-loss drugs currently on the market. Forging a collaboration agreement with CTS Ltd., a pharmaceutical leader in Israel. Advancing our IP with patent filings in the U.S., including the treatment of depression and dyskinesia, bringing our patent portfolio, to 27 granted patents and 24 pending patent applications across 15 patent families. Looking ahead, we believe that we are poised to achieve significant milestones that we hope to substantially enhance shareholder value through 2024. These include the initiation of the Phase I/IIa trial of CMND-100 for AUD, expanding our strategic alliances, advancing our obesity research and trials, as well as progressing our MEAI-based alcohol substitute for the consumer market. We stand on the threshold of a new era in psychedelic-based medical treatment, driven by innovation and a commitment to transforming lives. The journey ahead is filled with potential, and we eagerly anticipate sharing impactful updates with our shareholders."

08:36 EDT Optiva, GDi parnter for integrated BSS, OSS solutions - Optiva announced a strategic go-to-market partnership with GDi. The partnership will provide communication service providers with pre-integrated and tested BSS and OSS software. As the telecom industry embraces GenAI opportunities, unifying and integrating billing and charging customer data with network management and operations support data has never been more critical. Optiva and GDi bring decades of telecom industry experience to customers across the globe, working closely with large network operators, MVNOs and new market entrants. The partnership will enable rapid time to market for innovative new services for joint clients and optimize the upgrade and modernization of legacy BSS and OSS systems to meet customer expectations and improve operational efficiencies.

08:35 EDT Amprius Technologies selected to power AIBOT's aiEVTOL ecosystem - Amprius Technologies announced it has been selected by AIBOT to be its trusted battery partner. Amprius SiCore batteries will enable AIBOT's next-generation aiEVTOL vehicles, ushering in a new era in electric aviation. "AIBOT's focus on developing cutting-edge autonomous electric aircraft solutions aligns with our commitment to pushing the boundaries of battery technology," said Dr. Kang Sun, CEO of Amprius. "We applaud their strategy to validate their autonomous aircraft through a phased approach, accelerating their time-to-market. Our SiCore batteries offer unmatched performance in electric mobility, and we are confident that our technology can help AIBOT achieve their goal of creating a connected, autonomous, and ultra-safe aircraft ecosystem."

08:35 EDT Imax adds three new Imax With Laser locations in China - Imax and Bona Film Group are expanding their partnership with an agreement for three new Imax with Laser systems in China, set to begin operation starting in 2026. Imax and Bona Film Group have partnered since 2012 - this deal will bring the total number of Imax locations with Bona Film Group to 36. The agreement marks the first deal for the two companies post-COVID.

08:34 EDT Red Cat, Ocean Power partner for integration of Teal 2 Drones - Red Cat Holdings (RCAT) announces a partnership with Ocean Power Technologies (OPTT). The partnership will enable organizations using OPT's PowerBuoy and WAM-V platforms to deploy Teal 2 Drones as part of their strategy to leverage autonomous vehicles to assess and address maritime threats in real time. Red Cat's collaboration with Ocean Power Technologies and integration with OPT's maritime domain awareness solution adds to its robust tactical ecosystem of partnerships with leading companies to provide the best solutions to clients for their tactical missions. Other Red Cat hardware and software partners include Primordial Labs, Tomahawk Robotics, Athena AI, Teledyne FLIR, Reveal Technology, Immervision, and Doodle Labs, which enable capabilities such as computer vision, AI, and third-party apps.

08:34 EDT Hanesbrands, Duke University extend long-term apparel partnership - HanesBrands announces a five-year extension of its current apparel partnership with Duke University. The partnership renews HanesBrands exclusive rights to sell Duke's fanwear in the mass retail channel. "Passion for the Blue Devils runs deep in HanesBrands' home state of North Carolina as well as nationally, and we're proud to continue to support and engage their faithful fanbase," said John Fryer, HanesBrands President of Licensed Sports Apparel. "This is our longest extension to date with Duke, and it's testament that our partnership is helping to grow their market among loyal fans, alumni and students."

08:33 EDT One Stop Systems appoints Craig Powell as business development executive - One Stop Systems has expanded its business development team and appointed Craig Powell Business Development Executive. Under this new role, Powell will be responsible for expanding the Company's sales opportunities in U.S. and International defense and commercial markets. Most recently, Powell was Vice President of Business Development at Overwatch Imaging, a developer of automated, multispectral smart sensors and AI-enabled software solutions.

08:32 EDT Freddie Mac sells $104M in non-performing loans - Freddie Mac sold via auction 679 deeply delinquent non-performing residential first lien loans from its mortgage-related investments portfolio. The loans, with a balance of approximately $104 million, are currently serviced by Specialized Loan Servicing LLC and NewRez LLC, d/b/a Shellpoint Mortgage Servicing. The transaction is expected to settle in June 2024. The sale is part of Freddie Mac's Standard Pool Offerings. Freddie Mac, through its advisors, began marketing the transaction on March 6, 2024, to potential bidders, including non-profits and Minority, Women, Disabled, LGBTQ+, Veteran or Service-Disabled Veteran-Owned Businesses, neighborhood advocacy organizations and private investors active in the NPL market. Bids for the upcoming Extended Timeline Pool Offering, which is a smaller sized pool of loans, are due from qualified bidders by April 25, 2024. For the SPO offering, the loans were offered as one pool of mortgage loans. The pool consists of mortgage loans secured by geographically diverse properties. Given the delinquency status of the loans, the borrowers have likely been evaluated previously for loss mitigation, including modification or other alternatives to foreclosure, or are in foreclosure. Mortgages that were previously modified and subsequently became delinquent comprise approximately 47 percent of the aggregate pool balance. Additionally, purchasers are required to honor the terms of existing loss mitigation agreements and solicit distressed borrowers for additional assistance except in limited cases and ensure all pending loss mitigation actions are completed.

08:29 EDT Myriad reports results from real-world study of patients with depression - Myriad Genetics revealed results from a multi-year, real-world study of nearly 21,000 patients that indicated those with major depressive disorder had reduced healthcare utilization after taking the GeneSight Psychotropic test. The study demonstrated that the percentage of patients with hospitalizations was significantly reduced 180 days after GeneSight testing: 39% relative reduction in psychiatric-related hospitalizations. 29% relative reduction in hospitalizations for any reason. Significant reduction in hospitalizations for patients who were switched to a medication with no or moderate gene-drug interactions. The study found that, among patients who took the GeneSight test, there was a decrease in the proportion of patients who were prescribed medications with significant gene-drug interactions after taking the test: The percentage of patients who were prescribed medications in the significant gene-drug interaction category was reduced from 26.1% to 15.9%. The percentage of patients who were prescribed medications with no gene-drug interactions increased from 27.5% to 47%.

08:27 EDT ContextLogic urges stockholders to vote for Qoo10 transaction - ContextLogic reminded stockholders to vote at the upcoming special meeting of stockholders on Friday, April 12, 2024, at 10:00 a.m. Pacific Time. The ContextLogic Board of Directors recommends that stockholders vote "FOR" the proposed Asset Sale transaction with Qoo10. Upon closing of the transaction, ContextLogic will continue as a publicly traded company with ~$2.7 billion of net operating loss carryforwards. If the Company's stockholders approve the transaction at the Special Meeting on Friday, then the Asset Sale would be scheduled to close on April 16th. In that case, the Company estimates that its post-closing cash would range from $150-157 million. However, the estimate is based on an April 16th closing. As described in the Company's proxy materials for the Special Meeting, the cash consideration to be paid to the Company is subject to a purchase price adjustment based on the Company's cash balance at closing. Because of the Company's negative cash flow described in the proxy materials for the Special Meeting, every day that stockholder approval is delayed will very likely result in lower post-closing cash. The decrease could be material. Therefore, with the Special Meeting fast approaching, it is extremely important that stockholders vote as soon as possible, no matter how many shares they own. Leading proxy advisory firms Institutional Shareholder Services, Glass Lewis and Egan-Jones have all recommended that ContextLogic stockholders vote "FOR" the proposed Asset Sale. The newly reconstituted Board and leadership will evaluate opportunities to maximize the value of the Company's NOLs on behalf of stockholders and explore the opportunity for a financial sponsor to help realize the value of its tax assets. Maximizing the Company's post-closing cash will best position the Company's post-closing Board and leadership to pursue transactions that will utilize those tax assets for the benefit of ContextLogic stockholders. To ensure your shares are represented at the Special Meeting, ContextLogic stockholders are urged to vote online or by telephone by following the easy instructions on the previously provided proxy card. Electronic voting deadline is 11:59 p.m. Eastern Time on Thursday, April 11, 2024. The Company expects to complete the transaction in the second quarter of 2024, subject to the approval of ContextLogic's stockholders and other customary closing conditions.

08:25 EDT BriaCell showcases clinical data on Bria-IMT at AACR 2024 - BriaCell Therapeutics is presenting clinical data from its lead product candidate, Bria-IMT, in two posters of its three poster sessions during the 2024 American Association for Cancer Research Annual Meeting held from April 5-10 at San Diego Convention Center, San Diego, CA. Poster 1 - Title: Efficacy of Bria-IMT regimen in inducing CNS metastasis regression: Superior clinical benefit of Bria-IMT regimen - alone or combined with an immune check point inhibitor in advanced breast cancer patients with CNS metastatic disease: Clinical efficacy: 71% intracranial objective response rate, defined as the percentage of patients who achieve a complete response or partial response in intracranial tumors, achieved in patients with central nervous system metastases treated with the Bria-IMT regimen, either alone or in combination with an immune checkpoint inhibitor. These patients failed multiple prior treatments including 2 antibody-drug conjugates in one case. Clinical benefit is observed across all subsets of breast cancer. Safety profile: Absence of both interstitial lung disease, a common serious adverse event with ADCs, and no Bria-IMT-related treatment discontinuations underscore Bria-IMT's excellent tolerability and favorable safety profile. In summary, Bria-IMT's tumor reductions observed in all breast cancer subtypes in patients with intracranial disease underlines its potential clinical effectiveness in managing CNS metastatic disease in advanced breast cancer. BriaCell will continue to monitor the data in this subgroup of patients including a pre-planned subgroup analysis in the current pivotal Phase 3 study in advanced metastatic breast cancer. Treatment of patients with CNS metastatic disease represents a potential additional indication for market approval of Bria-IMT. Poster 2 - Title: Efficacy and safety of SV-BR-1-GM after progression on ADC in metastatic breast cancer patients: Notable progression-free survival benefit of Bria-IMT in ADC resistant advanced metastatic breast cancer: Phase 2 clinical data of the Bria-IMT regimen in 23 advanced metastatic breast cancer patients who failed multiple prior treatments including ADCs and CPIs are presented. Progression-free Survival Benefit: Median progression free survival, defined as the length of time during which a patient's cancer does not get worse, in heavily pre-treated patients of 3.5 months is comparable to that seen in similar studies in patients with a history of fewer prior treatments. Similarly, median PFS of 4.2 months in patients receiving the Bria-IMT pivotal phase 3 formulation is approximately twice the PFS figures reported for treatment of physician's choice in other similar studies. These PFS results suggest superior clinical efficacy considering the larger number of prior treatments in Bria-IMT patients vs those of the other studies. Clinical efficacy: PFS is similar or better than that of the last regimen in 48% of the patients suggesting Bria-IMT effectiveness in delivering clinical and survival benefits in these patients. Additionally, a clinical benefit rate, defined as percentage of patients whose disease shrinks or remains stable over a certain time, of 56% is observed in evaluable patients further highlighting clinical benefit. Subset specific clinical benefits: Study data to date suggests clinical benefit for multiple breast cancer subtypes including HR+/HER2- with a CBR following treatment, of 63%; HER2+ subtype with a 100% CBR and HR-/HER2 low subtype showing a CBR of 66%. Safety profile: There are no incidents of interstitial lung disease - a well-documented serious adverse event associated with ADCs, - in either ADC naive or ADC treated patients, and no treatment-related discontinuations of Bria-IMT. In summary, the data to date shows that Bria-IMT(TM) provides prolonged progression-free survival and clinical benefits in heavily pre-treated, ADC resistant breast cancer patients compared with those in other similar studies. BriaCell will be monitoring ADC resistant patients in its ongoing pivotal Phase 3 study of Bria-IMT and CPI in advanced metastatic breast cancer.

08:23 EDT Xencor appoints Cornelissen as Chief Financial Officer - Xencor announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Cornelissen has more than 20 years of experience in corporate financial planning, analysis and transaction support. Before joining Xencor, he was most recently vice president, corporate finance at Seagen, where he was instrumental in the company's transformation into a global, multi-product organization that generated over $2 billion in annual revenue.

08:19 EDT Westwood Holdings Group launches first exchange-traded fund - Westwood Holdings launched the Westwood Salient Enhanced Midstream Income ETF. The fund is the first Westwood Exchange-Traded Fund. MDST seeks to deliver current income and capital appreciation by investing in midstream energy companies, defined as companies and master limited partnerships that gather, transport, store and distribute crude oil, natural gas and other energy products. The ETF combines a high conviction, actively managed, energy-focused equity portfolio with an options overlay designed to produce enhanced income distributions for investors.

08:19 EDT Palo Alto Networks expands AI cybersecurity partnership with Google Cloud - Palo Alto Networks (PANW) and Alphabet's (GOOG) Google Cloud announced the most significant expansion of their partnership to date. Palo Alto Networks has extended and increased its commitment to Google Cloud with a ten-figure, multi-year commitment and named Google Cloud its AI and infrastructure provider of choice. Google Cloud has considered Palo Alto Networks its preferred next-generation firewall provider, and the expanded agreement solidifies that relationship. Palo Alto Networks Network Security platform with VM Series is embedded into Google Cloud and it will leverage Cloud Delivered Security Services offerings. Palo Alto Networks Cortex XSIAM, the AI-driven security operations platform, backed by Google's advanced cloud infrastructure and advanced AI services, aims to deliver global scale and near real-time protection across all cybersecurity offerings.

08:17 EDT InterContinental, Google Cloud announced expanded partnership - IHG Hotels & Resorts (IHG) and Google Cloud (GOOG, GOOGL) announced an expanded partnership that will fuel new customer experiences within the IHG One Rewards mobile app. With Google Cloud's technologies, IHG will launch a generative AI-powered travel planning capability that can help guests easily plan their next vacation directly in the IHG One Rewards mobile app in a suite of new features that will launch in the second half of 2024, creating a more dynamic digital guest experience.

08:16 EDT Papa John's deepens partnership with Bajco Group - Papa John's International announced plans to open 50 new restaurants by 2028 in partnership with franchisee Nadeem Bajwa and his company, The Bajco Group, which has grown over the past 20 years to become one of Papa Johns largest domestic franchisees. Furthering Bajwa's goal to own 500 Papa Johns restaurants, the new agreement will expand the Papa Johns footprint in The Bajco Group's existing markets across the Midwest and in Arizona, Pennsylvania and Florida, adding to the more than 200 restaurants the franchisee and his team currently operate.

08:15 EDT GDEV Inc. announcs launch of Pixel Gun 3D on PC platform - GDEV announces the launch of the mobile title Pixel Gun 3D on PC platform. The game was launched on Steam April 2, entering on debut the Top 20 most sold and Top 50 most played games. The peak concurrent Steam users count reached 25,000 players on the first day of release. The Steam version of Pixel Gun 3D recouped its PC platform development costs within the first day of release, making 5 times the average daily in-app purchases of the mobile version. The results were achieved without significant marketing investments, capitalizing on strong brand awareness across the globe. The PC version of Pixel Gun 3D offers enhanced graphics, as well as full cross-platform multiplayer functionality with mobile.

08:15 EDT AGM Group Holdings enters partnership with RDA - AGM Group Holdings is thrilled to announce the signing of a Memorandum of Understanding with Red Dot Analytics for collaborative efforts in constructing AI data centers. Under the MOU, RDA will strategically collaborate with AGMH to pioneer innovative initiatives in constructing AI hyper-connected GPU-driven data centers. Leveraging RDA's advanced Digital-twin platform and Company's purpose-built data centers for AI workloads, the partnership aims to validate designs, optimize predictions, improve PUE, and enable intelligent monitoring. Together, they will develop Digital-twin based, AI-driven solutions to enhance energy efficiency and sustainability in AI data centers. Pilot projects for AI data centers in Asia and Canada are set to commence, with further details to be discussed.

08:14 EDT Best Buy, Google Cloud and Accenture partner in generative AI for customer care - Best Buy (BBY), Alphabet's (GOOG) Google Cloud, and Accenture (ACN) announced a new collaboration that will involve deploying generative AI to improve the experience for Best Buy customers looking for support services. By leveraging Google Cloud's generative AI technology, Best Buy is creating new ways for customers to get solutions. It is anticipated that Best Buy's U.S. customers will be able to connect with a gen AI-powered virtual assistant for self-service support starting in late summer 2024. The assistant can help with things like troubleshooting product issues, rescheduling or combining order deliveries, or managing software, Geek Squad subscriptions and My Best Buy Memberships. In the coming months, Best Buy will also launch new gen-AI enabled capabilities for customer care agents to use while interacting with a customer across various internal platforms. Best Buy will work with Google Cloud and Accenture to develop an AI-driven assistant specifically for its front-line employees serving customers nationwide.

08:12 EDT Astria Therapeutics appoints Agarwal to board of directors - Astria Therapeutics (ATXS) announced the appointment of Sunil Agarwal, M.D., to its Board of Directors. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience. Agarwal currently serves on the Board of Directors of Arvinas and was previously a Board member of Calithera Biosciences (CALA), MyoKardia, and Vitrisa Therapeutics.

08:11 EDT Dynatrace expands go-to-market partnership with Google Cloud - Dynatrace (DT) announced an expanded go-to-market, GTM, partnership with Google Cloud (GOOGL). Together, the two companies will enable more customers worldwide to adopt the Dynatrace platform on Google Cloud for AI-powered analytics and automation of their cloud-native environments to achieve their digital transformation goals. The GTM motions include joint sales enablement and marketing initiatives, including customer solution workshops, marketing campaigns, and events.

08:11 EDT NCR Atleos' ATM as a Service selected by AZFCU - NCR Atleos Corporation announced that $3.3 billion-asset Arizona Financial Credit Union, AZFCU, has selected Atleos' ATM as a Service to increase operational efficiencies within the self-service banking channel while improving the member experience. "This is an exciting time for AZFCU as we continue to grow our membership and expand into new areas across the state. We needed a way to support this scale with added operational efficiencies and a robust member experience," said Chad Forkenbrock, EVP & Chief Operating Officer of AZFCU. "With Atleos' ATMaaS, we will be able to bring new functionality, faster innovation and greater reliability and uptime to our members while also benefitting from the predictable cost structure and more time to focus on strategic growth plans."

08:09 EDT Discover announces strategic collaboration with Google Cloud - Discover (DFS) announced a strategic collaboration with Google Cloud (GOOG, GOOGL) to introduce generative AI technology into its customer care centers. This collaboration aims to enhance the customer and agent experience, and improve agent productivity, offering faster, more personalized, and efficient resolutions. Using Google Cloud's AI platform, Vertex AI, Discover will empower its nearly 10,000 contact center agents with gen AI-driven tools with capabilities such as: Intelligent document summarization: Vertex AI will analyze and summarize complex policies and procedures, providing agents with information at their fingertips and rapid insight to answer customer needs. Real-time search assistance: Using natural language, agents can access vast knowledge bases to suggest relevant information during live interactions, so they spend less time searching and more time helping customers.

08:09 EDT Inspired Entertainment receives non-compliance notification from Nasdaq - Inspired Entertainment received a standard notification letter from the Listing Qualifications Department of the Nasdaq Stock Market stating the Company was not in compliance with the requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Form 10-K for the year ended December 31, 2023 with the Securities and Exchange Commission. This notification has no immediate effect on the listing of the Company's common stock on Nasdaq. Under the Nasdaq rules, the Company has 60 calendar days, or until June 3, 2024 to file the 2023 Form 10-K or to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rule. If the Company submits a plan to Nasdaq, which Nasdaq accepts, Nasdaq can grant an exception of up to 180 calendar days from the filing's due date, or until September 11, 2024, to regain compliance. However, if the Company fails to timely regain compliance with Nasdaq Listing Rule 5250(c)(1), the Company's common stock will be subject to delisting from Nasdaq. The Company currently intends to file the 2023 Form 10-K by no later than April 15, 2024.

08:08 EDT Galectin Therapeutics says DSMB recommends continuation of NAVIGATE study - Galectin Therapeutics reported the outcome of its fifth independent data and safety monitoring board meeting for NAVIGATE, its seamless, adaptive, Phase 2b/3 study of belapectin in patients with cirrhotic portal hypertension caused by Metabolic Dysfunction-Associated SteatoHepatitis. The objective of this fifth DSMB meeting was to further review the emerging tolerance and safety profiles of belapectin. Based on its deliberation, which included an unblinded review of the data collected thus far, the DSMB concluded that NAVIGATE can continue as designed, without modifications. The Phase 2b/3 NAVIGATE study is a global, seamless, adaptive, randomized, placebo-controlled, double-blind trial. This is the first study of its kind in cirrhotic patients with an innovative adaptive design and an innovative primary outcome of efficacy, the prevention of esophageal varices, a clinical marker of portal hypertension which is an essential mechanism underlying the relentless progression of the disease. The adaptive study includes two stages: The Phase 2b portion, or Stage 1, has been fully enrolled with 357 patients who have clinical signs of portal hypertension, no cirrhosis decompensations, and no esophageal varices. Portal hypertension is the consequence of the unrelenting inflammatory and fibrotic process occurring in the liver and dramatically increases the risk of developing esophageal varices, a potentially life-threatening complication of liver cirrhosis. Enrolled patients have been randomized to receive every two weeks a blinded infusion of belapectin at 2 mg/kg/LBM or 4 mg/kg/LBM or placebo. An interim analysis of safety and efficacy will be conducted once the last patient randomized into Stage 1 has been followed up for 18 months, and has had a second esophago-gastric endoscopy to evaluate for the presence or absence of esophageal varices. The results of this stage 1 interim analysis will determine if the study progresses into the Phase 3 portion of the trial, or Stage 2 , and which of the pre-specified protocol adaptations are to be integrated into this second stage. The Stage 1 interim analysis has three possible outcomes: stop NAVIGATE because of overwhelming efficacy or because of futility, or initiate NAVIGATE Stage 2 because there is a favorable conditional probability of success regarding the final analysis that will take place at the end of Stage 2. In this third scenario, adaptations to be selected include the choice of the best dose of belapectin and the final number of new patients to be randomized for ensuring an adequate study power for the Final Analysis. The topline results from the Interim analysis of the Phase 2b (Stage 1) portion of NAVIGATE is expected in the fourth quarter of 2024.

08:08 EDT Iveda Solutions, ClearView partner to enhance public safety - Iveda announced a collaboration with ClearView Asset Protection to help improve local public safety systems, such as AMBER Alerts, major interstate highways, sports stadiums, and more. Leveraging AI-powered surveillance technology, IvedaAI will use data from existing cameras and infrastructure to intelligently monitor and alert for threats including suspicious persons, missing or endangered children, smoke and fire, traffic flow issues, as well as facial and license plate recognition. "By working together with ClearView Asset Protection, we are continuing our mission to deliver solutions that help protect the people and places that matter most, implementing cutting-edge technology for the greater good," said David Ly, Iveda CEO and founder. "In cases of child abductions, every minute and second counts. Through the power of AI, law enforcement agencies are armed with an extra set of eyes, ones that never blink, to help accurately locate and track individuals and/or vehicles in real time by uploading pre-existing images and vehicle descriptions to the IvedaAI platform."

08:06 EDT Nice Actimize announces new integrated fraud management platform - NICE Actimize announced the availability of IFM 11, a new release of its market leading, AI-driven fraud management and detection platform. The new release leverages recent advancements in artificial intelligence together with NICE Actimize's unique collective intelligence capabilities to introduce unprecedented fraud detection accuracy, agility and efficiency to protect financial services firms and their customers from the next generation of AI-driven fraud and scams. "Financial institutions are facing a surge in fraud attacks, as criminals continue deploying AI to conduct scams," said Craig Costigan, CEO, NICE Actimize. "NICE Actimize is currently the only solution provider with a complete end-to-end fraud management platform offering fraud prevention and detection, strategy, and operations all leveraging powerful AI capabilities purpose-built to tackle the evolving, faster-paced digital fraud landscape."

08:05 EDT WisdomTree reports current total AUM $107.23B as of March 2024 - WisdomTree released monthly metrics for March 2024, including assets under management and flow data by asset class. Monthly Commentary: Higher fee funds drove the over $1.2 billion of net inflows in March and nearly $2 billion of net inflows YTD, generating a positive fee impact; Generated net inflows in 6 of our 8 major product categories, including double-digit annualized flow growth in Equity, Fixed Income, Commodities and Cryptocurrency; equity franchise generated $2.4 billion of YTD net inflows and a 17% pace of YTD organic growth; WisdomTree's trust company charter granted by the New York State Department of Financial Services will enable WisdomTree Prime to onboard New York resident customers, and also allows WisdomTree to offer products and perform services under DFS supervision with associated legal protections; Including the forthcoming launch in New York, WisdomTree Prime will be available in 41 states and to approximately 75% of the U.S. population

08:05 EDT Norfolk Southern reaches settlement in East Palestine derailment class action - Norfolk Southern has reached a $600M agreement in principle to resolve a consolidated class action lawsuit relating to the East Palestine derailment. If approved by the court, the agreement will resolve all class action claims within a 20-mile radius from the derailment and, for those residents who choose to participate, personal injury claims within a 10-mile radius from the derailment. In March 2023, the company made commitments to address three long-term concerns of residents: drinking water, home values, and healthcare. Already, the company has announced programs for drinking water and home value assurance. Individuals and businesses will be able to use compensation from the settlement in any manner they see fit to address potential adverse impacts from the derailment.

08:03 EDT J & J Snack Foods acquires Thinsters, terms not disclosed - J&J Snack Foods announced its acquisition of Thinsters, the deliciously crunchy cookie made with real, simple ingredients. This strategic move strengthens J&J Snack Foods' position as a leader in providing America's favorite delicious and fun snacks.

08:01 EDT Charles River announces rare disease gene therapy collaboration with Axovia - Charles River Laboratories International announced a plasmid DNA contract development and manufacturing organization collaboration with Axovia Therapeutics Ltd. Charles River will manufacture High Quality gene of interest plasmid to support the development of Axovia's gene therapies for ciliopathies, including Bardet-Biedl Syndrome, a condition with limited treatment options and no cure. "We are committed to supporting Axovia in the pursuit of creating treatment options for patients living with ciliopathies. The Charles River team brings decades of expertise in HQ plasmid development, and we look forward to using these capabilities to make a difference for patients." - Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River

07:47 EDT Jacobs to Design Miami-Dade wastewater treatment plant expansion and upgrades - Jacobs was selected by the Miami-Dade County Water and Sewer Department to design upgrades for the county's three wastewater treatment plants. Under the six-year professional services agreement, Jacobs will support upgrades aimed at modernizing aging infrastructure, improving operational performance, mitigating climate change impacts and addressing the system's resilience across the department's wastewater treatments plants and system. Jacobs' certified trainers have also provided operator training to Miami-Dade County staff to help renew their water and wastewater licensure.

07:37 EDT Sonoma expands Microcyn NPWT Solution products in the U.S. - Sonoma Pharmaceuticals announced the expansion of its Microcyn Negative-Pressure Wound Therapy Solution products in the United States. Microcyn Negative-Pressure Wound Therapy Solution, an innovation in advanced wound care, is now available in convenient sizes of 250mL, 450mL, and 990mL. Designed to meet the diverse needs of healthcare professionals and patients, Microcyn NPWT Solution is a cutting-edge solution that provides effective cleaning and irrigation for wounds with precision and reliability. Microcyn NPWT Solution complements a wide array of negative-pressure therapies. Sonoma's solution delivers optimal wound cleansing and management, promoting faster healing and improved patient outcomes. It does not contain antibiotics, and as a result, it does not promote antibiotic resistance and helps reduce odor by removing necrotic tissue.

07:34 EDT Marimed announces 2nd adult-use Thrive Wellness dispensary in Maryland - MariMed announced the closing of its acquisition of the operating assets of Our Community Wellness & Compassionate Care Center in Prince George's County, Maryland on April 5th. Just prior to closing, MariMed paid the state's adult-use conversion fee and subsequently received an adult-use license to sell retail cannabis products from the Maryland Cannabis Administration MCA. The acquired dispensary has been closed since July 1st, 2023. The Company expects to reopen the dispensary and begin adult-use retail sales by the end of the second quarter, upon regulatory approvals.This marks MariMed's second adult-use Thrive Wellness dispensary in Maryland that the company owns and will be located at 9520 Marlboro Pike in Upper Marlboro, Maryland. MariMed also owns and operates a Thrive Wellness dispensary in Annapolis and a cultivation and processing facility in Hagerstown. MariMed plans to continue seeking additional dispensary acquisitions to achieve the maximum of four allowed in the state.

07:32 EDT Ranpak Holdings announces launch of Geami MV wrapping system - Ranpak Holding announced the launch of the Geami MV wrapping system, a compact powered converter that delivers an optimal mix of productivity and simplicity. The continued rise in e-commerce means shippers are looking to optimize, setting up their warehouses with many pack stations that are configured for spatial efficiency and productivity. Our customers are seeking solutions that help them conserve space but maximize throughput across the warehouse," said Omar Asali, Chairman & Chief Executive Officer of Ranpak.

07:31 EDT Eagle Materials announces start up of Texas Lehigh Cement Company - Eagle Materials (EXP) announced plans for Texas Lehigh Cement Company, a 50/50 joint venture between Eagle and Heidelberg Materials North America (HDELY), to start-up a new slag cement facility in Houston, Texas this summer. Construction for the new slag cement facility is substantially complete; once finished, the plant will have an annual manufacturing capacity of approximately 500,000 tons to supplement Texas Lehigh's cement manufacturing plant in Buda, Texas. "Today's announcement is an important step for Eagle Materials in extending our ability to meet the demand needs of our customers in a fast-growing market like Texas, especially as other cementitious alternatives like fly ash diminish in availability," commented Michael Haack, President and CEO of Eagle Materials Inc. "We are committed to continued progress across our environmental stewardship initiatives, and the new Texas Lehigh Cement Company slag facility is another exciting step towards increasing the sustainability of our business."

07:30 EDT Defense group awards Gilat SOTM/SOTP modem order for 'millions' of dollars - Gilat Satellite Networks announced that a leading Defense Organization awarded the company multimillions of dollars for the development of a next-generation SOTM/SOTP modem. This next-generation military modem is aimed to set a new standard for mission flexibility, with fast-to-deploy and easy-to-operate capabilities while meeting the most stringent specifications. The modem will deliver high-speed satellite communications for on-the-move and on-the-pause missions. It will further provide secure, highly reliable broadband C4I satellite communications that ensure battlefield information superiority for warfighters. The modem's advanced technologies will maximize link availability, optimize bandwidth usage, and enable high throughput anywhere, and anytime in the most challenging field conditions.

07:25 EDT Omega Therapeutics presents preclinical data on precision epigenomic control - Omega Therapeutics announced the presentation of new preclinical data demonstrating the anti-tumor effect of a MYC-targeting epigenomic controller in models of EGFR inhibitor-resistant non-small cell lung cancer at the American Association for Cancer Research Annual Meeting 2024, taking place in San Diego, California, April 5 - 10. The Company also presented preclinical data validating a novel pharmacodynamic biomarker assay for monitoring on-target engagement and activity of its clinical-stage EC candidate, OTX-2002. Abstract 1726: Targeted epigenomic control of MYC as a strategy to treat EGFR inhibitor-resistant NSCLC: Key Findings: The combination of a MYC-directed EC with osimertinib, a third generation EGFRi blocker, led to enhanced downregulation of MYC protein levels and synergistically inhibited viability of EGFR-T790M mutant NSCLC cells in preclinical models; NSCLC cells resistant to osimertinib through the EGFR C797S mutation or epithelial to mesenchymal transition retained sensitivity to epigenomic downregulation of MYC expression with NSCLC MYC-EC in multiple in vitro models; These results support potential development of a NSCLC MYC-EC in EGFR-mutant NSCLC as a combination therapy with osimertinib, and as a monotherapy in osimertinib-resistant NSCLC. Abstract 2417: Detection and quantification of site-specific DNA methylation from liquid biopsies as a pharmacodynamic biomarker of OTX-2002, a novel MYC-targeting epigenomic controller; Key Findings: Development of a new DNA methylation assay consisting of a minimal hybridization capture panel to evaluate CpG methylation events across a ~50 kilobase target region; Ultra-sensitive detection of methylation events at the MYC locus down to the theoretical limit of 1 in 104 copies of MYC; Demonstration of highly specific on-target engagement and methylation by OTX-2002 in liquid biopsies from mice bearing human hepatocellular carcinoma xenografts.

07:21 EDT Nurix eligible for $2.5B in research collaboration with Sanofi for 'STAT6' - Nurix Therapeutics (NRIX announced an extension of the ongoing research program with Sanofi (SNY) for STAT6 . STAT6 is a key drug target in type 2 inflammation. "STAT6 is a key transcription factor within the IL-4/IL-13 signaling pathways which act as drivers of inflammation in allergic conditions. These conditions are currently treated with injectable monoclonal antibody therapies, which are designed to impede IL-4/IL-13 signaling," said Gwenn M. Hansen, Ph.D., chief scientific officer of Nurix. "Preclinical data from our STAT6 degraders show that targeted degradation of this key transcription factor provides a rapidly acting and potent blockade of signaling. We anticipate nominating a clinical candidate from this advanced preclinical program in the coming twelve months." Under the collaboration agreement, Nurix is deploying its proprietary drug discovery platform to identify novel agents that use E3 ligases to induce degradation of specified drug targets. Sanofi has an option to license drug candidates resulting from the work, and Nurix retains its option to co-develop and co-promote future products in the United States under programs for which Nurix has exercised its option. For those programs for which Nurix exercises its option to co-develop and co-promote, the parties will split U.S profits and losses evenly and Nurix will be eligible to receive royalties on ex-U.S. sales on all optioned products. Upon signing the agreement in December 2019, Sanofi made an upfront payment of $55M and subsequently paid an additional $22M one year later to expand the scope of the collaboration. Under the agreement, Nurix remains eligible for up to a total of $2.5B in potential future milestones as well as royalties on future products. With this announcement, Nurix and Sanofi have agreed to extend the research term for the ongoing STAT6 program with the goal of nominating a development candidate in the first year of the extended term.

07:15 EDT ARKO's GPM Investments launches $4.99 pizza program - GPM Investments, a wholly owned subsidiary of ARKO Corp., has launched multiple deals and value-oriented promotions featuring its $4.99 pizza to last through the middle of May 2024 and lead into the summer season. As Spring rolls in, enrolled fas REWARDS loyalty members can purchase a delicious pizza, available in cheese and pepperoni, coupled with tasty beverages for inflation-busting prices. Through May 14, 2024, enrolled fas REWARDS loyalty members will be able to choose among a handful of fantastic offers, including pairings of pizza with certain Pepsi-Cola beverages. The offers leverage strong vendor relationships to provide terrific value and a tasty meal to GPM's loyal customers.

07:13 EDT NuStar Energy, Sunoco announce expiration of HSR Act waiting period - Sunoco LP (SUN) and NuStar Energy L.P. (NS) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, HSR Act, in connection with Sunoco's pending acquisition of NuStar. The expiration of the waiting period under the HSR Act satisfies an important condition necessary for the completion of the transaction.

07:12 EDT CareDx to present cardiothoracic advancements at 2024 ISHLT meeting - CareDx announced that CareDx and study collaborators will be presenting the latest data featuring CareDx's cardiothoracic portfolio at the International Society for Heart and Lung Transplantation, ISHLT, 44th Annual Meeting & Scientific Sessions, taking place from April 10-13 in Prague, Czech Republic. "We are proud to have a leading presence once again at this pivotal heart and lung transplant meeting. We are especially pleased to share new results from our SHORE registry validating the clinical utility of surveillance using HeartCare testing," said Alex Johnson, President of Patient and Testing Services, and member of the Office of the CEO.

07:11 EDT CPI Card Group announces expansion with new production facility in Indiana - CPI Card Group announced the construction of a new manufacturing facility in Fort Wayne, Indiana that will double the size for this location. This new facility exemplifies CPI's commitment to meeting the evolving needs of its customers and driving innovation in the payments technology industry. "CPI is proud to continue operating in the Fort Wayne community, where we are locally engrained with a high-performing team," said John Lowe, President and Chief Executive Officer. "After years of planning, we are excited to announce this major milestone for our 'Factory of the Future'. This is the first time in CPI's nearly 30-year history that we've had the opportunity to build a manufacturing facility to our specifications. It's a chance to provide our employees with the latest and most advanced tools, and will solidify CPI as a top workplace now and in the future."

07:10 EDT Tilray no longer expects to generate positive adjusted free cash flow for 2024 - For its fiscal year ending May 31, 2024, the Company is now guiding to an Adjusted EBITDA target of $60 million to $63 million. In addition, the Company no longer expects to generate positive adjusted free cash flow for the full fiscal year 2024, due to delayed timing for collecting cash on various asset sales. Management's guidance for Adjusted EBITDA is provided on a non-GAAP basis and excludes transaction expenses, restructuring charges, litigation costs, facility start-up and closure costs, purchase price accounting step-up, changes in fair value of contingent consideration and other items carried at fair value, non-operating income, and other non-recurring items that may be incurred during the Company's fiscal year 2024, which the Company will continue to identify as it reports its future financial results. Management's guidance for adjusted free cash flow is provided on a non-GAAP basis and excludes our growth capex, projected integration costs related to HEXO and the Craft Acquisition, and the cash income taxes related to Aphria Diamond.

07:09 EDT Alkermes' ALKS 2680 improves wakefulness in Phase 1b narcolepsy study - Alkermes announced positive topline results from the narcolepsy type 2 - NT2 - and idiopathic hypersomnia - IH - cohorts of a phase 1b, proof-of-concept study evaluating ALKS 2680, the company's novel, investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy. ALKS 2680 data demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency on the Maintenance of Wakefulness Test vs. placebo at all doses tested. ALKS 2680 was generally well tolerated in both patient populations at all doses tested. The company plans to initiate a phase 2 study in patients with NT2 in the second half of 2024. Alkermes expects to submit results from this phase 1b, proof-of-concept study to a peer-reviewed journal for publication and to present additional ALKS 2680 study results at upcoming scientific meetings.

07:08 EDT ProMIS publishes data on pathogenic proteins as treatment target for ALS - ProMIS Neuroscience announced the publication of supportive preclinical data in the Journal of Biological Chemistry in an article titled, "Tryptophan residues in TDP-43 and SOD1 modulate the cross-seeding and toxicity of SOD1." ProMIS is developing antibodies selectively targeting misfolded forms of TDP-43 and SOD1. ALS is a fatal neurodegenerative disease of motor neurons. Toxic aggregates of superoxide dismutase-1 and TAR DNA-binding protein 43 in motor neurons are characteristic of ALS.The study showed that these two proteins interact such that misfolding of TDP-43 leads to misfolding and aggregation of SOD1 in a cell system and promotes motor neuron damage in zebrafish.

07:07 EDT Blue Owl Capital acquires Prima Capital Advisors for $170M - Blue Owl Capital announced the creation of Blue Owl's Real Estate Finance strategy with the acquisition of Prima Capital Advisors for the aggregate consideration of $170M. Prima manages approximately $10B in assets on behalf of institutional investors and select high net worth individuals. The acquisition is expected to close in the second or third quarter of 2024, subject to customary closing conditions. Prima, founded in 1992 by Gregory White, is a real estate lender focused primarily on investing in commercial mortgage-backed securities. Prima is majority owned by Stone Point Capital, an alternative investment firm based in Greenwich, Connecticut. Blue Owl's acquisition of Prima will be funded through a combination of approximately $157M of equity and approximately $13M in cash, subject to certain closing consideration adjustments. In addition, there is potential for up to $35M of earnout consideration in the form of equity. Upon closing of the acquisition, Prima employees are expected to join Blue Owl.

07:06 EDT Aeva Technologies expands presence in Europe, new automotive COE in Germany - Aeva announced that it is expanding its presence in Europe with a new Automotive Center of Excellence, COE, in Germany to support its growing momentum with automotive OEM customers. Additionally, autonomous vehicle industry expert Axel Gern has joined the company as Head of Engineering in Germany and will lead the COE. Most recently Gern served as Senior Vice President of Engineering and Managing Director for Torc Robotics Europe.

07:04 EDT Aterian teams with Mercado Libre e-commerce platform in Mexico - Aterian (ATER) announced that it has begun selling select products on the Mercado Libre (MELI) marketplace in Mexico as part of a partnership with Mercado Libre. Aterian is currently selling products from its home and kitchen category on Mercado Libre's Mexico marketplace and plans to add more products in the near future. Aterian's longer term vision entails expanding its product portfolio and presence across all Mercado Libre marketplaces throughout Latin America. "We are excited for the opportunity to partner with Mercado Libre to deliver value to its customers," said Joseph Risico, Aterian's Co-CEO. "We are optimistic about the opportunity to grow alongside Mercado Libre in the years to come."

07:03 EDT Augmedix integrates with Andor Health for ambient clinical documentation - Augmedix has integrated with Andor Health, an AI-first cloud-based communication and collaboration platform for virtual care. The alliance aims to harness the power of ambient documentation to transform the clinician-patient interaction landscape in mission-critical virtual care settings. As part of this collaboration, Andor and Augmedix will integrate physician clinical note creation directly within ThinkAndor Virtual Visit capability for ambulatory with an AI-generated note available seconds after the virtual session.

07:02 EDT Trio Petroleum retires $2.6M convertible note - Trio Petroleumannounced that on April 8, 2024, filed a Form 8-K with the Securities and Exchange Commission detailing the terms and conditions under which the Company retired $2.6 million in outstanding convertible notes. These notes had been previously funded in two tranches in October of 2023. As previously reported in a Current Report on Form 8-K filed with the Securities and Exchange Commission on October 4, 2024, Trio Petroleum Corp., a Delaware corporation entered into a Securities Purchase Agreement with an institutional investor for convertible debt financing in an aggregate amount of up to $3,255,000, to be funded in up to two tranches in which the Company would issue senior secured original issue 7% discount convertible promissory notes in an aggregate principal amount of $3.5 million. The Company issued to the Investor two promissory notes in an aggregate principal amount $2,550,000 in two tranches. On April 2, 2024, the Company and the Investor mutually agreed to permit the acceleration of more than six monthly payments pursuant to the Second Tranche Note, so that the entire outstanding balance of the Second Tranche Note could be repaid.

06:55 EDT Piedmont Lithium's strategic review supports production ramp-up at NAL - Piedmont Lithium (PLL) announced that, following a detailed operational review, the joint venture partners of North American Lithium - NAL - have agreed to complete several ongoing capital project initiatives and continue operations with the goal of completing ramp-up activities to achieve steady state production within 2024. NAL is jointly owned by Piedmont - 25% - and Sayona Mining (SYAXF) - 75% -. Process plant recoveries are now exceeding internal expectations. March month-to-date lithium recoveries were 69%, exceeding the ramp-up target of 67%, with global recovery of 62% during the July 2023 through March 2024 period. Current plant throughput rates are in line with forecast expectations and product quality remains consistent. The joint venture partners have conducted an operational review to assess the pace of the production ramp-up in the context of a challenging lithium price environment. The review concluded that operations are generally ramping-up as planned, and that completion of two capital improvement projects - a crushed ore storage dome and crushed ore re-feed system, both expected to be commissioned in May 2024 - should help operations achieve production increases and meaningful unit cost improvements. Unit mining costs also are expected to improve as operations move past underground workings and into fresh ore near the end of 2024.

06:51 EDT ANI Pharmaceuticals announces launch of Baclofen Oral Suspension - ANI Pharmaceuticals announced the launch of Baclofen Oral Suspension, a generic version of the reference listed drug Fleqsuvy. U.S. annual sales for Baclofen Oral Suspension total approximately $39M, according to IQVIA data.

06:46 EDT CNX Resources nears completion of Kiski Water Line prokect - CNX Resources is nearing completion of its Kiski Water Line project, which will serve the Company's local operational needs, reduce the local impact of natural gas development, and potentially optimize regional water resources by providing additional reliable water infrastructure to area communities. The $20M project is expected to be completed in June 2024 and will serve future natural gas development in the area. During voluntary or mandatory water conservation periods, the 20" Kiski Water Line is expected to serve as the primary alternative to water purchased from the Municipal Authority of Westmoreland County. The water line also significantly reduces the need for CNX to utilize water trucking in the County, mitigating the community impact of the Company's local operations. Importantly, the project also offers unprecedented potential future opportunity to improve and optimize regional water infrastructure and resources. With regulatory approvals and minor equipment modifications, the water line could be used to provide MAWC and the reservoir with optionality during Kiski River high flow periods. Such activity could better position the Beaver Run Reservoir to maintain normal service during seasonally dry periods and mitigate drought and residential conservation risk. The project significantly improves area water resource resilience. Other potential community applications that could benefit from the project include freshwater agricultural needs, industrial use, and other various community needs. Realizing the project's full potential will require partnership and input from various stakeholders, and CNX looks forward to engaging in discussion with the Pennsylvania Department of Environmental Protection, local officials, the business community, and the MAWC.

06:33 EDT Akamai announces launch of Akamai Shield NS53 - Akamai Technologies announced the launch of Akamai Shield NS53, a product that protects on-premises Domain Name System infrastructure from resource exhaustion attacks. These attacks overwhelm servers to the point that they can no longer respond to valid DNS queries. The new offering complements Akamai Edge DNS, which is a comprehensive cloud-based DNS solution, and Akamai Prolexic, the distributed denial-of-service protection platform for Layer 3 and Layer 4 attacks.

06:10 EDT BlackBerry, AMD collaborating in robotics hardware platform - BlackBerry (BB) announced a collaboration with AMD (AMD) designed to revolutionize next-generation robotic systems by enabling new levels of low latency and jitter, and repeatable determinism. Together, the companies will address the critical need for 'hard' real-time capabilities in robotics-focused hardware with a platform that delivers enhanced performance, reliability, and scalability for robotic systems in industrial and healthcare. The platform combines BlackBerry QNX expertise in real-time foundational software solutions and the QNX Software Development Platform with heterogeneous hardware solutions powered by the AMD Kria K26 SOM that features both Arm and FPGA programmable logic-based architecture. With Kria, an Arm sub-system can power the advanced capabilities of the QNX microkernel real-time operating system while allowing users to run low latency, deterministic functions on the programable logic of the AMD Kria KR260 robotics starter kit. This combination aims to enable sensor fusion, high-performance data processing, real-time control, industrial networking, and reduced latency in robotic applications. The integrated solution is now available to customers.

06:05 EDT TRI Pointe opens new divisions in Orlando, Florida and the Coastal Carolinas - Tri Pointe Homes announced that it is expanding its national footprint with the opening of new divisions in Orlando, Florida and the Coastal Carolinas. Operations for the Coastal Carolinas, which build upon the company's presence in the Raleigh and Charlotte markets, will be located near Charleston, South Carolina, while the Florida office will be based in Orlando, Florida, elevating Tri Pointe Homes' national presence within two of the fastest-growing regions in the nation.

06:05 EDT KBR awarded engineering services contract by First State Hydrogen - KBR has been awarded an engineering services contract by First State Hydrogen, Inc. to support the feasibility and development of its first clean hydrogen production facility in the U.S. mid-Atlantic region. KBR will provide engineering services to study the feasibility of developing a clean hydrogen production facility through electrolysis powered by renewable energy. The study is part of First State Hydrogen's vision to provide clean hydrogen for Delaware and the U.S. mid-Atlantic and help the region meet its sustainability goals.

06:03 EDT BrainStorm announces agreement with FDA on SPA for Phase 3b ALS trial - BrainStorm Cell Therapeutics received written agreement from the U.S. Food and Drug Administration, under a Special Protocol Assessment (SPA), on the design for a Phase 3b trial of NurOwn in amyotrophic lateral sclerosis. The SPA agreement with the FDA validates the clinical trial protocol and statistical analysis of the planned Phase 3b trial of NurOwn, demonstrating their adequacy for addressing objectives that support a future BLA in ALS. BrainStorm anticipates commencement of the Phase 3b study in 2024, after reviewing the protocol with investigators, securing study site Institutional Review Board approvals, and engaging with appropriate members of the ALS community. The Phase 3b trial will be a two-part, multicenter, study designed to assess the efficacy and safety of NurOwn in patients with ALS. The entry criteria will enroll participants earlier in the course of their disease, having the onset of ALS symptoms, including limb weakness, within the prior 24 months, all ALSFRS-R items 2 at Screening, and upright slow vital capacity greater than=65% of predicted for gender, height and age. Patients will also be allowed to receive concomitant treatment of an approved standard of care. Part-A is a double blind, placebo-controlled period of 24 weeks duration. Up to approximately 200 patients are planned to be enrolled and randomized 1:1 to NurOwn or placebo treatment groups. There will be a screening period of six to nine weeks, during which eligible participants will undergo a single bone marrow aspiration procedure to procure the mesenchymal stem cells that will be used to manufacture each participant's NurOwn treatment for the duration of the trial. Patients will then be randomized 1:1 and treated with NurOwn or placebo via three repeated intrathecal injections, once every eight weeks. All eligible patients who complete Part-A will have the option of entering Part-B, open-label extension period of 24 weeks duration, where all participants will receive three repeated intrathecal injections of NurOwn, once every eight weeks. The primary efficacy endpoint is the change in the Revised Amyotrophic Lateral Sclerosis Functional Rating total score from baseline to Week 24. Primary inference from the trial will be based on a p-value from the combined assessment of function and survival to account for mortality observed in the trial. Cerebrospinal Fluid and blood samples will be collected for analysis of biomarkers of neuroinflammation, neurodegeneration, and neuroprotection. An independent Data Monitoring Committee will monitor the safety of the trial participants.

06:02 EDT OppFi announces 12c per share special dividend, $20M share repurchase plan - OppFi announced that its Board of Directors has declared a 12c per share special dividend to be payable on May 1 to holders of record of the company's Class A common stock as of the close of business on April 19. In addition, the Board authorized a new $20M share repurchase program. The repurchase program will expire in April, 2027.